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Introduction 

Introduction 
The syndrome of hepatic encephalopathy 
Hepatic encephalopathy (HE) is a neuropsychiatnc syndrome associated with severe liver 
disease. Clinical symptoms range from minimal changes in mental state and neuromuscular defects 
to unresponsive coma. 1-' The syndrome of HE can be divided into three major groups: HE 
associated with liver cirrhosis, HE associated with acute liver necrosis and HE associated with 
errors of metabolism (table I). 
HE is most often observed in patients with cirrhosis of the liver, either as a result of decreased 
hepatic parenchymal function or as a result of increasing portal-systemic shunting without liver 
insufficiency (also defined as portal-systemic encephalopathy 1 - ')_ In patients with cirrhosis, HE 
can be induced or aggravated by a number of precipitating factors (table 2). ' 
HE associated with acute liver necrosis has a dramatic clinicaJ course, leading to acute liver failure 
in most patients. Apart from jaundice, HE can be the first alarming symptom of acute liver failure. 
The degree of HE is a strong predictor of outcome in acute liver failure~ patients who only reach 
grade II HE have a possibility of spontaneous recovery of 65 - 70 %; with grade III HE it is 40 -
50 % and in grade IV HE it is only 20 %. In the majority of patients with grade III HE cerebral 
edema is present, which can evolve to an increase in intracranial pressure, cerebral herniation and 
death. ' 
Table 1 Hepatic encephalopathy: the syndromes 
HE liver cirrhosis I. decreased hepatic parenchymal function 
2. increased portal-systemic shunting 
3. precipitating factors (table 2) 
HE acute liver necrosis 
HE errors of metabolism I. urea cycle enzYIue deficiency (OTC, CPS) 
2. organic acidemias 
3. Rcyc's syndrome 
(secondary urea cycle deficiency and Iivcr necrosis) 
HE associated with errors of metabolism includes inborn errors, like: urea cycle enzyme 
defects (predominantly carbamyl phosphate synthetase (CPS), ornithine transcarbamylase (OTC» 
and organic acidemias. In addition, Reye's syndrome in children results in secondary urea cycle 
enzyme deficiency, fatty infiltration of the liver and liver necrosis. 6 - 8 Reye's syndrome is 
characterised by progressive HE in a previously healthy child. Classically, this syndrome has a 
biphasic course, in which progressive HE develops after a prodromal febrile illness (an upper 
respiratory tract infection or chickenpox) and an interval of 5 - 7 days without symptoms. 12-13 
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HE associated with acute liver necrosis, urea cycle enzyme deficiencies and Reye's syndrome can 
have a rapidly progressive course, and survival of patients is dependent on the degree of HE and 
cerebral edema, Symptomatic treatment of cerebral edema and hyperammonemia often fails to 
prevent cerebral herniation, structural brain damage and death, Although liver transplantation is 
urgently indicated in patients with progressive cerebral complications, a suitable donor liver is 
often not available in time, The understanding of the mechanism of HE and cerebral edema 
formation could help to develop therapeutic strategies specifically directed to these cerebral 
complications, Therefore, in this thesis there is a focus on the pathophysiology of HE, 
Of all syndromes of HE, the syndrome of HE associated with liver cirrhosis is most prevalent. 
HE in cirrhosis is often the result of decreased hepatic parenchymal damage or increased portal-
systemic shunting. However, in about 60 to 70 % of cases one or more precipitating factor can 
be identified (table 2), HE in cirrhosis can be treated satisfactory, either by dietary protein 
restriction, lactulose, antibiotics, or sodium benzoate, or by eliminating one or more precipitating 
factors. As a last therapeutic option, liver transplantation is available to cirrhotic patients with 
liver insufficiency and recurrent episodes of HE. 4,9·11 
However, two major groups of patients with cirrhosis can be identified, which have an Increased 
risk of chrornc'or recurrent episodes of HE, and which cannot be satisfactory treated: Firstly, 
patients with contra indications for liver transplantation {e,g, old cirrhotic patients and patients 
treated with a Transjugular Intrahepatic Portosystemic Shunt (TIPS)); Secondly, patients with 
neuropsychological or neurophysiological defects, without clinical signs of HE, also defined as 
subclinical hepatic encephalopathy (SHE), 12 In this thesis we focussed on the syndrome of SHE, 
because its diagnostic criteria, its clinical implication, and its effect on daily functioning is largely 
unknown. 
12 
Introduction 
Table 2 Factors precipitating hepatic encephalopathy in cirrhosis 4 
preclpltatlng factor 
- Excess dietary protein 
- Constipation 
- Gastrointestinal haemorrhage 
- Infection I bacterial peritonitis 
- Blood transfusion 
-Azotemia 
- Hypokalemia 
- Systemic alkalosis 
- Dehydration 
(fluid restriction, diuretics, excessive paracentesis, 
diarrhea due to osmotic laxatives) 
- Arterial hypotension 
(gastrointestinal haemorrhage, peripheral vascular 
dilatation) 
- Anaemia 
- Use ofbenzodiazepines 
- Usc of other psychoactive drugs 
- Portosystemic shunts 
(spontaneous, surgically, Transjugular Intrahepatic 
Portosystemic Shunt (TIPS» 
- Progressive hepatic parenchymal damage 
- Hepatocellular carcinoma 
possible mechanism 
Increased ammonia production 
Increased dUTusion of anmlonia across 
blood-brain-bamer 
Reduced metabolism of toxins because of hepatic 
hypoxia 
Activation of GABA-benzodiazepine receptors 
eNS depressant effect 
Reduced hepatic metabolism of toxins because of 
diversion of portal blood 
Reduced hepatic metabolism of toxins because of 
decreased fimctional reserve 
PATHOPHYSIOLOGICAL ASPECTS OF HEPATIC ENCEPHALOPATHY 
Ammonia and glutamate 
Ammonia is still the leading factor considered to have a causative relation with regard to 
HE. 13 There are three factors that support a causative relation 14 : Firstly, ammonia is usually 
elevated in patients with HE; IS, 16 in patients with other hyperammonemia syndromes, like urea 
cycle enzyme deficiencies, organic acidemias and in neonates with transient hyperammonemia, 
hyperammonemia is accompanied by encephalopathy; 6 • • Secondly, experimentally induced 
hyperammonemia induces signs of encephalopathy; 17, II Thirdly, treatment directed to lowering 
blood ammonia levels - using either protein restriction, lactulose. oral antibiotics or sodium 
benzoate - reverse signs afHE. 14,16 
13 
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The mechanism of ammonia toxicity is still largely unknown. In essence, ammonia affects brain 
metabolism in three ways: either by interference with cell metabolism, with electrophysiologic 
membrane function, or with neurotransmitter function. 13,19,20 The interference of ammonia with 
neurotransmitter function is of interest, because it is still unknown whether anunonia itself or 
ammonia-related amino acids - like glutamate and glutamine - are the toxic factor. Previous 
studies at our department on the effect of ammonia on brain neurotransmitter function has led to 
the hypothesi~ that glutamate neurotoxicity may be related to structural brain damage and to HE. 
27,45 
Glutamate is the principal excitatory neurotransmitter in the mammalian brain, 21,22 and there is 
substantial evidence showing its involvement in a large number of neurological diseases, like 
epilepsy, Alzheimer disease and in stroke-induced brain damage. 21· 2l The following experimental 
data also support the involvement of glutamate in HE: Firstly, total brain glutamate levels are 
significantly reduced in autopsied brain tissue of patients with acute and chronic liver disease who 
died in hepatic coma, ".21 suggesting altered glutamate metabolic pathways between neurons and 
glial cells; 26 Secondly. extracellular concentrations of glutamate are increased significantly in 
portacaval shunted rats, 27 and in rabbits with acute hyperammonemia and with acute liver failure, 
25 probably as a result of an ammonia-induced decrease in glutamate re-uptake into astrocytes. 
26 Increased post-synaptic stimulation by glutamate down-regulates non-NMDA-glutaminergic 
receptors (kainate and AMP A) in experimental acute liver failure, 28 which results in a relative 
over-exposure ofthe NMDA receptor. Over-exposure of the NMDA receptor leads to increased 
calcium influx intraceliularly, disturbance of ion homeostasis, and cellular swelling. Eventually 
tlus neurotoxicity leads to cell death. 2l 
The GABA-bellzodiazepine receptor complex 
y-aminobutyric acid (GAllA) is the most important inhibitory neurotransmitter in the 
mammalian brain, and it comprise 30 % of the total neurotransmitter content. 29, 30 Binding of 
benzodiazepines to the GAllA-benzodiazepine receptor complex potentiates the inhibitory effect 
of GAllA. 29 Shafer and Jones 31 were the first to postulate, that GAllA synthesized by intestinal 
bacteria escaping hepatic detoxicification. could induce signs of HE. Initial studies on this issue 
supported this concept: Firstly, increased GAllA-like activity was found in serum of patients with 
HE; 32 Secondly, enhanced transfer of u-aminobutyric acid and GAllA across the blood brain 
barrier was found in rabbits with acute liver failure, 33 and thirdly: GABA receptors were down-
regulated in brains of patients with HE." However, these findings could not be confirmed by 
others. 12 Therefore, attention shifted to the concept of endogenous benzodiazepine activity, 
stating that HE may be induced by the accumulation of benzodiazepine-like substances in the 
blood. 35 Although increased "endogenous" benzodiazepine activity was found in patients with 
HE, 36 results may have been biased by exogenous benzodiazepine use and by benzodiazepine-
14 
Introduction 
like substances in the diet. The ultimate test to evaluate the role ofbenzodiazepines in HE is the 
application of a benzodiazepine antagonist. However, controlled trials on this issue in patients 
with HE show conflicting results. 37·40 The unresolved issue of the GABA-benzodiazepine made 
us decide to re-evaluate the efficacy of the benzodiazepine antagonist flumazenil at our 
department, using objective criteria. 
Thyroid hormone metabolism 
Altered thyroid hormone metabolism is a common finding in patients with chronic liver 
disease. "." Low triiodothyronine (T3) and low thyroxine (T, ) levels have been described, 
without clinical signs of hypothyroidism. In general, central regulation of the thyroid gland is 
preserved in patients with chronic liver disease. The observed changes in thyroid hormone 
metabolism have therefore been classified as non-thyroidal illness (NTJ). n." A case-control 
study performed at our department indicated, that serum total T3 has strong independent 
predictive power for HE. " In addition, a recent case-report suggested, that supplementation of 
thyroid hormone may improve symptoms of HE ... We therefore hypothesize, that altered thyroid 
hormone metabolism has a role in the pathogenesis of hepatic encephalopathy. 
Other potential fields in the pathophysiology of HE 
I!yptophan 
Tryptophan was found to induce HE in Eck fisula dogs. 47 In cirrhotic patients with HE, 
tryptophan is increased, compared to patients without HE. " Tryptophan is a precursor of 
serotonin (5-HT), and increased serotonin turnover was observed in brains of rats with a 
portacaval shunt and ammonia infusion. of9 More recently, studies in brain tissue from cirrhotic 
patients who died in hepatic coma revealed increased activity of the serotonin-degrading enzyme 
monoamine oxidase. so In addition, increased densities of post-synaptic serotonin binding sites 
(5HT2 ) were found. These findings indicate, that serotonin metabolism is increased in HE, 
probably accompanied by a serotonergic synaptic deficit." The exact mechanism by which 
tryptophan could contribute to HE is under investigation, with focus on the kynurenic pathway. 
Through the kynurenine pathway L-kynurenine is produced out of tryptophan. L-kynurenine can 
modulate excitatory neurotransmission; in addition, from L-kynurenine, quinolinic acid is 
formed. This substance has very potent excitatory properties and it could induce excitotoxic 
damage to the brain. 52,13 The following experimental data confirm the possible role of quinolinic 
acid in HE: In rats with a portacaval shunt whole brain quinolinic acid was increased. " In 
cerebrospinal fluid of patients who died in HE quinolinic acid was 3-fold increased, compared to 
control subjects. " In children with congenital hyperanunonemia a 2 -10 - fold increase in CSF 
quinolinic acid was found; the increase was significantly higher in neonates in hyperammonemic 
coma, compared to older children without coma. 56 
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Manganese 
Pallidal hyperintensity on Tl-weighted MRI is a confirmed finding in patients 
with cirrhosis S7,18, which may be related to manganese accumulation. " Analysis of blood 
samples of cirrhotic patients showed significantly increased manganese levels, as compared to 
controls, and manganese levels were correlated with the degree of pallidal hyperintensity,'" The 
role of manganese accumulation in the pathogenesis of HE - and especially its effect on 
dopaminergic neurotransmission in basal ganglia - remains undefined. 
Glytamine and myo-inositol 
Brain ammonia is detoxified in astrocytes by glutamine synthetase. In experimental 
hyperammonemia, brain glutamine levels are significantly increased 18, 2S· 27 , and in patients with 
acute liver failure, a 6-fold elevation of glutamine was observed. 61 Glutam.ine accumulates in 
astrocytes, which could result in astrocytic swelling and the formation of brain edema. Inhibition 
of g1utanline synthesis by methionine-sulfoximine prevents brain swelling in rats afier portacaval 
anastomosis. 62 ·61 In patients with cirrhosis, HE is rarely associated with brain edema formation, 
suggesting that the osmotic effect of glutamine accumulation is compensated by osmoregulatory 
mechanisms. 65 Studies on the organic osmolite myo-inositol in patients with chronic HE showed, 
that myo-inositol is decreased intracellularly (measured by NMR spectroscopy), indicating that 
astrocytes try to preserve their osmotic balance by extruding myo-inositol.66 In addition, in rats 
with a portacaval shunt, a time-dependent change in organic brain osmolytes was observed. 61 
The implications of these osmoregulatory changes for the pathophysiology of HE is still 
undefined, 
16 
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SUBCLINICAL HEPATIC ENCEPHALOPATHY 
Hepatic encephalopathy is tradionally graded into four grades, ranging from subtle mental 
impairment to unresponsive coma. The classical clinical grading system is presented in table 3a. 
We have had considerable difficulties in defining the various items. The application of this system 
by two experienced clinicians resulted in discrepancies in at least one third of patients. 4S 
T_ble3_ 
Grade 0 
Grade 1 
Grade 2 
Grade J 
Grade4 
Table 3b 
Grade 0 
Grade 1 
Grade 2 
Grade J 
Grade 4 
Clinical grading of hepatic encephalopathy 
No abnonnality 
Trivial lack of awareness 
Euphoria or anxiety 
Shortened attention span 
Impaired perfonnance of addition 
Lethargy or apathy 
Minimal disorientation of time or place 
Subtle personality change 
Inappropriate behaviour 
Impaired perfornlance of subtraction 
Somnolence to semi'stupor, but responsive to verbal stimuli 
Confusion 
Gross disorientation 
Coma (unresponsive to verbal or noxious stimuli) 
Adapted clinical grading of hepatic encephalopathy 
absence of at least three of the following abnormalities: 
inverted sleep pattern 
disturbed memory 
impaired calculation 
slowness of speech 
presence of at least two of these abnormalities, or one abnormality in 
association with a flapping tremor 
presence of at least two of the following abnormalities: 
lethargy 
disorientation in time 
flapping tremor 
presence of at least two of the following abnormalities: 
coma 
a state in which the patient must be urged repeatedly to open his 
eyes or execute a C<lmmand 
disorientation in place 
disorientation in person 
17 
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Therefore, we now use an in-house grading system, aiming at a more reproducible classification 
of patients, and based on the classical four stages (table 3b). 
Still, clinical grading lacks precision and is subject to considerable inter-observer variability. 12 
In addition, the difference between grade 0 ("no abnormality") and grade 1 ("trivial lack of 
awareness") is poorly defined; the adapted grading system by Van der Rijt does not solve this 
problem. Most patients with cirrhosis either have grade 0 or grade 1 HE. However, a considerable 
number of patients without clinical HE (grade 0) have subtle deficits in neuropsychiatric functions, 
using neuropsychological and neurophysiological tests. "·10 This abnormality has been defined 
as subclinical hepatic encephalopathy (SHE). 11 
The prevalence of SHE varies between 30 . 84% in patients with liver cirrhosis, dependent on 
the diagnostic criteria used.68 • 70 At our department, studies on the diagnosis of SHE have been 
performed, using psychometric tests (Number Connection test A and Digit Symbol Test), and 
automated EEG analysis. SHE is defined present in a patient without clinical signs of HE, if at 
least one psychometric test is abnormal and/or ifthere is abnormal slowing of the EEG." ·72 The 
prevalence of SHE as diagnosed by these criteria is about 23 %. Presence of SHE is correlated 
with the severity of liver disease, ranging from 14 % of patients with Child-Pugh A to 45 % of 
patients with Child Pugh H/C. In addition, older patients with cirrhosis with higher arterial 
ammonia level~ have an increased risk to develop SHE, compared to younger patients. 11 
The significance of the diagnosis SHE is subject to debate. ,," Recent studies show, that SHE 
has a negative influence on daily functioning. 74, 75 In addition, several investigators suggested, that 
there is a relation between SHE and the subsequent development of episodes of clinical hepatic 
encephalopathy. ,,76 However, studies on the natural history of SHE and its prognosis with 
respect to development of clinical hepatic encephalopathy and survival are lacking. 12.72 
To limit the inter-observer variability of clinical grading, automated EEG analysis has been 
developed at our department. 77 This method is now standard procedure in the evaluation of HE 
in our clinic, and it is used for the diagnosis of SHE. 
Studies have indicated, that the EEG of patients with clinical HE can vary during the day, and 
especially after a meal. 18 To be able to use automated EEG analysis as an optimal diagnostic test, 
data on its variability during the day should be available. 
18 
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Focus of research on hepatic encephalopathy in 1994 
In summary, in 1994, when protocols were written that form the basis of the studies 
included in this thesis, our research on the pathophysiology of HE primarily focussed on 
ammoniaMinduced alterations in glutamate neurotransmission, stmctural brain damage (neuronal 
and glial marker proteins), the GABA-benzodiazepine receptor complex (flumazenil) and thyroid 
honnone metabolism. Four studies on the pathophysiology addressing some of these subjects, 
are included in this thesis. 
Our clinical research on HE primarily focussed on the diagnosis and implications of subclinical 
hepatic encephalopathy (SHE). Four studies on SHE are included in this thesis. 
AIMS OF THE THESIS 
Studies on the pathophysiology 
To evaluate structural changes in the brain of rabbits with encephalopathy associated 
with acute liver failure and acute hyperammonemia (chapter 1.1) 
To study the effect of the glutamate receptor antagonist MK-80 I on encephalopathy and 
survival of rabbits with encephalopathy associated with acute liver failure and acute 
hyperammonemia (chapter 1.2) 
To study the role of thyroid hormone metabolism in the pathophysiology of hepatic 
encephalopathy (chapter 1.3) 
To study the clinical and electro physiological effect of flumazenil in patients with hepatic 
encephalopathy (chapter 1.4) 
Studies on subclinical hepatic encephalopathy 
To study the variability of automated EEG analysis during the day in patients with 
subclinical and clinical hepatic encephalopathy (chapter 2.1) 
To study the effect of subclinical hepatic encephalopathy on daily functioning 
(chapter 2.2) 
To study the diagnostic applicability of symptoms specifically related to subclinical 
hepatic encephalopathy (chapter 2.3) 
To study the prognostic significance of subclinical hepatic encephalopathy 
(chapter 2.4) 
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Abstract 
Neuronal and glial cell marker proteins were quantified in order to evaluate the 
possibility of increased proteolysis in the brain of rabbits with acute liver failure and acute 
hyperammonemia. Acute liver failure was induced by a two-stage devascularisation procedure. 
Acute hyperammonemia was induced by a prolonged infusion of ammonium acetate, which 
simulates the plasma ammonia level in acute liver failure. Control animals received an infusion 
of sodium/potassium acetate. After development of severe encephalopathy, the animals were 
sacrificed (13.7 ± 1.3 hours in rabbits with acute liver failure and 20.2 ± 0.8 hours in rabbits 
with hyperammonemia) (x ± S.E.M.) and brains were dissected into cerebral cortex, 
hippocampus, cerebellum and brain stem. The total protein content and the concentration of 
neuronal cell marker proteins NSE (neuron specific enolase), NF- 68 and NF-200 (68 kD and 
200 kD neurofilament polypeptides) and the glial cell marker proteins GFAP (glial fibrillary 
acidic protein) and S-100 were determined. Total protein content was decreased in brain stem 
in acute hyperammonemia only. The content of neuronal and glial cell markers was not 
affected in either of the two conditions. However, low molecular weight proteolytic fragments 
of the NF 68kD polypeptide were observed in the hippocampus of three out of six animals in 
both experimental groups. No proteolytic degradation was observed for GFAP. The results 
show that, in experimental encephalopathy associated with acute liver failure and acute 
hyperammonemia, no major changes occur in the marker proteins. The finding of proteolytic 
fragments of the NF 68kD polypeptide indicate that the neuronal population is affected prior 
to glial alterations. These findings are in agreement with the concept that acute hepatic 
encephalopathy is reversible and induces only slight structural changes. 
Introduction 
Hepatic encephalopathy is a neuropsychiatric syndrome caused by serious liver disease. 
Hyperammonemia appears to be an important causative factor. 1 Ammonia disturbs normal 
brain function in many ways, 1,2 but the precise mechanism of encephalopathy induction is 
unknown. We have concentrated on the interference of hyperammonemia with excitatory 
neurotransmission.3.4 The amino acid glutamate is the most common excitatory 
neurotransmitter S and the metabolism of glutamate is closely related to that of ammonia. 6,7 
Increased extracellular concentrations of glutamate were found in the brains of rabbits with 
acute ischemic liver necrosis, galactosamine-induced liver necrosis and acute 
hyperammonemia and in the cerebrospinal fluid of rats with acute ischemic liver necrosis. 3,4,lf 
Furthermore, increased glutamate concentrations are found in the cerebrospinal fluid of 
patients with hepatic encephalopathy. 9,ID,1I 
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This indicates that the receptors are exposed to increased glutamate levels in 
hyperammonemia. In vitro experiments suggest that hyperammonemia comprorruses glutamate 
fe-uptake by astrocytes. 12,13 Moreover, astrocytes are critical for ammonia metabolism 7,13 and 
the most characteristic neuropathological finding in hepatic encephalopathy is the 
transformation of astrocytes in grey matter into Alzheimer type II glia. IS· IS The extracellular 
brain glutamate concentration is found to increase 3.5-10 fold in brain ischemia 16 and this is 
considered crucial to the development of neuronal deficits and cell death in stroke, 
hypoglycemia and epilepsy. 17 In ischemia, glutamate toxicity is mainly mediated through 
activation of postsynaptic receptors. The neurons swell within minutes ", and die within a day 
due to excessive calcium influx. 19,20 The extracellular brain glutamate concentration is 
increased 2-5 fold in experimental acute liver failure. 3._ Consequently, glutamate neurotoxicity 
may be of importance also in the pathogenesis of hepatic encephalopathy. 
Glutamate receptor mediated neurotoxicity induces degenerative andlor proliferative changes 
in the brain. The concentration of neuronal and glial cell marker proteins have been used to 
monitor these effects. These markers include: neuron specific enolase (NSE), a neuronal 
cytoplasmatic enzyme 21, NF-68 and NF-200, two polypeptide-fragments of neuronal 
intermediary filaments ", glial fibrillary acidic protein (GF AP), a fibrillary component of the 
glial intermediary filament 23 and S-\ 00 which is a glial cytoplasmatic protein. 21 
The appearance of breakdown products of neuronal and glial intermediary filaments is a 
sensitive indicator of excitatory cell injury. 2.. This report concerns degenerative and 
proliferative changes in neurons and glial cells in experimental liver acute failure and acute 
hyperammonemia. 
Animals and methods 
Anima/s. Nineteen New Zealand white rabbits weighing 2-3 kg were used. Acute liver 
failure (ALF) was induced by a two-stage liver devascularisation procedure as described 
earlier. 2S,26 Under anesthesia a laparotomy was performed: a loose ligature was placed around 
the hepatoduodenal ligament and guided through a plastic tube through the abdominal wall to 
the subcutaneous layer of the left subcostal region, and a small-diameter (5 mm) side-to-side 
portacaval shunt was constructed. During this procedure the superior mesenteric artery was 
clamped to reduce splanchnic blood stasis. To correct acidosis after release of the vascular 
clamps 5 ml 8,4% sodium bicarbonate were given intravenously. Postoperatively the rabbits 
were given 50 ml 10% glucose subcutaneously, followed by standard laboratory chow and 
water ad libitum. 
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The second day after the operation acute liver failure was induced by tightening the 
loose ligature around the hepatoduodenal ligament after giving 50 mg amoxicillin 
intravenously. The rabbits were subsequently placed in a restraining box. To prevent 
hypoglycemia 10% glucose was given intravenously, starting at a volume of 3 mVhr and 
adjusted according to the plasma glucose level when necessary. When survival after induction 
of liver ischemia was less than 6 hours, death was considered to be related to postoperative 
complications. Only rabbits surviving for at least 6 hours were included for analysis. Acute 
hyperammonemia (AMM) was induced by a prolonged intravenous ammoniumacetate 
(NH,Ac) infusion simulating the plasma ammonia pattern of rabbits with acute liver failure. 26 
After insertion ofa Venllon cannula (diameter 0.8 mm, Viggo, Helsingborg, Sweden) into an 
earveio, NH4Ac was infused at a constant volume of 6 mVhr, starting with an initial dose of 
0.8 mmol/kg/hr, which was subsequently increased by 0.2 mmoVkg/hr every two hours. Aller 
16 hours the dose remained constant. Control rabbits (C) received a sodium-potassium acetate 
(NaKAc) solution, which was infused as in the NH,Ac experiments. 
Laboratory measurements. Arterial blood samples were taken at 0,1 and 2 hours, and 
every two hours thereafter for ammonia determination, using the enzymatic method. 27 Blood 
glucose levels were measured hourly (Haemoglucotest, Boehringer, Germany). 
Clinical signs of encephalopathy. At regular time-intervals the rabbits were put into a 
large cage for clinical evaluation. Rabbits with acute liver failure exhibit two easily 
recognizable stages of encephalopathy. " Stage A is characterized by a disturbed righting 
reflex: the animal will not get up immediately when placed on its side. In stage B the rabbit 
lays in the cage and cannot achieve to the sitting position, even after stimulation, and usually 
cannot lift its head. All rabbits with acute liver failure and all rabbits receiving NH,Ac were 
sacrificed during encephalopathy stage B. The rabbits receiving NaKAc were sacrificed at the 
same time as the rabbits receiving NH,Ac. All animals were sacrificed through decapitation. 
Brain sampling. Brains were rapidly removed and dissected. Dissection was 
performed on a plastic plate placed on ice. Cerebral cortex (left and right fronto-temporal 
parts), hippocampus (left and right), cerebellum and brain stem were dissected. Immediately 
thereafter samples were packed in plastic bags, which were stored at -70'C untill further 
analysis. 
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Quantitalive analysis of neuronal alld glial cell marker proteins. Brain samples were 
sonified at 90'C and a dot immunobinding procedure was perfonned:"·29 brain samples were 
diluted in buffer (120 mM KCI, 20 mM NaCI, 2 mM NaHCO, and 5 mM hepes, pH 7.4/0.7% 
Triton X-100 (vol/vol) to contain ca. 0.5 ~g total protein per IlL. Using the Minifold II slot-
blot apparatus as a template, 20 ~L samples were blotted onto nitrocellulose membrane filters. 
The filters were fixed in 10% acetic acid and 25% 2-propanol. The remaining reactive sites on 
the filters were blocked with a blocking solution containing 0.5% gelatin. The filters were 
incubated overnight at room temperature in an antibody solution (blocking solution, 0.1% 
Triton X-100 and antisera). The antibody preperations were diluted as follows: S-100, 1/500; 
GFA, 1/2500; NSE, 11500; NF-68, 11500 and the supernatant of the monoclonal antibody FE3 
against NF-200, 11100. The specificities of the antibodies have been described in detail. 23 
After antibody incubation, the filters were reacted with '25 I-protein A in the blocking solution 
containing 0.1 % Triton X-I 00 at a radioactivity of 150,000-200,000 cpm/ml. Finally the fiIters 
were dried, cut and assayed for radioactivity in a gamma counter (Automatic Gamma Counter 
and Sample Change System 54, Nuclear Data Inc.). For the determination of the NF-200 
polypeptide with a monoclonal antibody, rabbit immunoglobulins to mouse immunoglobulins 
(diluted I: 1000 in the antibody solution) were used as bridging antibodies since protein A 
binds very weakly to mouse immunoglobulins. The amount of each of the specific proteins in 
the unknown samples were quantified. First, a reference sample was prepared from a mixture 
of all the control samples from the frontotemporal cerebral cortex and standard curves were 
constructed by dilution. The amount of protein was found by interpolation on the standard 
curves. It was expressed in arbitrary units (AU), defined as the amount of protein in 20 ~L of 
the reference sample. The total protein concentration in the samples was determined with a 
commercial assay (pierce) in microtiter plates. Bovine serum albumin was used as standard. 29 
Qualitative allalysis oj lIeurollal alld glial illtermediary fllamellts. Equal amounts of 
proteins applied to SDS-PAGE gels were separated by electrophoresis with a linear 6-12 % 
acrylamide gradient. 30 The proteins were then tranferred to 0.45 ~m nitrocellulose membranes 
(Schleicher & SchueIl, Keen, NH, USA) for antibody incubation. 31 The antibody preparations 
were diluted in the following manner: rabbit anti-human GFA, 1/10000 and rabbit anti-bovine 
neurofilament NF 68, 1/1000. Preparation of a rabbit antisera used in this study, as well as 
certification of their specificities, were described elsewhere. 32 The goat-anti-rabbit IgG-
alkaline phosophates as the secondary antibody and BCIPINBT as substrate (BiO-RAD, 
Richmond, CA, USA). 
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Necropsy. Necropsy was performed to exclude gross pathological abnormalities. In the 
animals with acute ischemic liver cell necrosis the liver was examined carefully to confirm 
tightening of the ligature. 
Statistics. The results are presented as mean ± S.E.M. For statistical analysis unpaired 
Student's I test and the Student-Newman-Keuls procedure was used. Statistical significance 
denotes p<O.OS. 
All experiments were approved by the Ethical Committee on Animal Research of the Erasmus 
University Rotterdam. 
Results 
Encephalopathy due to acute liver failure was characterized by complete loss of spon-
taneous activity, impaired body posture, absence of the righting reflex, decreased muscle tone 
and a diminished reaction to a painful stimulus. Rabbits with encephalopathy from acute 
hyperammonemia exhibited similar symptoms, but also had severe ataxia. All animals with 
acute liver failure and all animals with acute hyperammonemia developed encephalopathy 
stage B, after 13.7 ± 1.3 and 20.2 ± 0.8 hours respectively (n~6, mean ± S.E.M., p < O.OS). 
Two rabbits with acute liver failure died just after stage B was recognised. Control studies 
were performed for 18.8 ± 0.8 hours. During the experiments increases of arterial ammonia 
levels in the rabbits with acute liver failure and acute hyperammonemia were similar in pattern. 
At the start of the experiments ammonia levels were significantly higher in ALF-rabbits (120 ± 
24 ~mol/l), due to their portacaval shunt, compared to AMM-rabbits (49 ± 2.8 ~moVl) or 
CON-rabbits (SI ± 3.8 ~moVl)(p<O.OS). During encephalopathy stage B the plasma ammonia 
levels in ALF-rabbits (S18 ± 97 ~moVI) and AMM-rabbits (S3S ± 117 flmoVI) did not differ 
significantly (p>O.OS) (table I). 
Table 1 Mean arterial ammonia during acute liver failure, acute hyperammonemia and 
control experiments 
1'=0 1'=4 hours 1'=8 hours 1'=12 hours Tend 
CON 51 ±3.8 40± 4.8 33±O.8 29 ± 1.9 35 ± 3.4 
ALF 120±24+ 247 ± 26+ 313±37+ 481 ± 109+ 518±97* 
AMM 49 ± 2.8 216 ± 23+ 315±34+ 370 ± 39+ 535± 117* 
Ammonia levels are expressed in ftOlOllL. CON: controls, ALF: acute liver failure~ AMM: ammonia infusion. T.:=O: 
baseline; T:=4,8 and 12 hours: time after baseline; T end: encephalopathy stage 8 (end of experiment). *p <0.05 vs. 
controls (Student Newman Keuls test). 
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Total protein content was measured of cerebral cortex, hippocampus, brain stem and 
cerebellum (table 2). During acute liver failure no changes of the total protein content were 
found. During acute hyperammonemia total protein content of the brain stem was found to be 
decreased compared to the control rabbits (p<0.05); no changes were found in cortex, 
hippocampus and cerebellum. 
Table 2 Brain total protein content after acute liver failure, acute hyperammonemia 
and control experiments 
CON ALF AMM 
(0=6) (0=6) (0=6) 
cortex 1 73± 1.5 73 ± \.4 73 ± 1.2 
hippocampus I 83± 1.1 86± 1.3 8\±\.4 
cercbellwn 72 ±O.4 74 ± 2.3 70± 1.3 
brainslem 66 ± 1.0 66 ± 1.1 + 60 ± 1.9+ 
Total protein content is expressed in ltg/rug wet weight ± S.E.M. CON: controls; ALF: acute liver failure; AMNf: 
anunonia infusion. I mean of sample of right and left side. 
The amounts of the neuronal (NSE, NF68 and NF 200) and glial (GF AP and S-100) 
cell marker proteins of cerebral cortex and hippocampus during acute liver failure and acute 
hyperammonemia were not different from those found for control rabbits (table 3). Similar 
resuIts were obtained for the cerebellum and brain stem (not shown). 
Sonified brain samples containing equal amounts of the NF 68kD polypeptide and the GFAP 
from the hippocampus were investigated by the immunoblot technique using polyclonal rabbit 
antisera against the polypeptides. 24 In both experimental groups, three out of six experimental 
animals showed a visual increase of low molecular breakdown products of the neurofilament 
68 kD polypeptide with molecular weights of 46 and 48 kD compared to the controls. The 
increase seemed to be more pronounced among the animals infused with ammonia. No 
alterations of the immunoblot staining pattern of GFAP in hippocampus from these animals 
were detectable (not shown). 
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Table 3 
cerebral cortex 
GFAP 
S-IOO 
NSE 
NF68 
NF200 
hlppocantpUli 
GFAP 
S-IOO 
NSE 
NF68 
NF200 
neuronal alld glial markers ill hepatic encephalopathy 
Neuronal and glial marker proteins after acute liver failure, 
acute hyperammonemia and control experiments 
CON ALF AMM 
(n=6) (n=6) (0=6) 
0.91 ±O.II 0.80± 0.04 0.93±0.16 
0.95 ± 0.04 0.98 ±0.04 0.96 ± 0.06 
0.79±0.0) 0.84 ±O.O) 0.78±0.04 
0.84±0.04 0.83±0.0) 0.94±0.06 
0.86 ± 0.06 0.85 ± 0.07 0.85±0.08 
0.9)±0.IO 0.82±0.04 O.95±0.11 
0.94 ± 0.05 0.95 ±O.O) 0.9) ±0.06 
0.84 ±0.04 0.86 ± 0.05 0.78±0.02 
0.83±0.02 0.88 ±0.06 0.81 ±0.05 
0.70 ± 0.05 0.69 ± 0.0) 0.69±O.06 
Proteins are expressed in arbitrary units (AU) ± S.E.M., defined as the amOlmt of protein in 20 ilL of a reference 
sample (see Methods). CON: controls, ALF: acute liver failure; AMM: ammonia infusion. 
Discussion 
The concentration of neuronal (NSE, NF-68 and NF-200) and glial (GFAP and SIOO) 
cell markers was unaffected in experimental encephalopathy due to acute liver failure and 
acute hyperammonemia; the total protein content was lowered only in the brain stem of 
animals infused with ammonia. However, an increased amount of low molecular breakdown 
products ofNF 68kD was found in the hippocampus of both treated groups. The degradation 
pattern of NF68 is similar to that induced by calcium activated neutral proteases in vitro, " 
since the major breakdown products have an approximate molecular weight of 50 kD. Similar 
breakdown products were observed after in vivo stimulation of hippocampal NMDA receptors 
in rats. 3-4 
Changes in glial proteins are the principal finding in hepatic encephalopathy. Cultured 
astrocytes showed a selective decrease in GFAP after four days of exposure to 10 mM 
ammonium chloride 35 and there was a selective loss of GF AP in the grey matter of patients 
who died with liver cirrhosis and Alzheimer type II gliosis. 36,37 Alzheimer type II astrocytes 
are not seen before 5 - 10 days of treatment. IS.'" The mechanism for this loss of GF AP is 
unknown. Increased calcium-dependent proteinase activity and decreased protein synthesis 
have been proposed. 35.39 This specific loss of GFAP is a "marker" for hepatic encephalopathy: 
other pathological conditions invariably show an increase in GF AP. 13 Predominantly structural 
proteins appear to be affected in hepatic encephalopathy, since the content of S-I 00 is not 
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altered. 40," The exposure time (less than 24 hours) in the present study may have been too 
short for quantitative changes in the proteins to occur. The qualitative change in NF68 seen in 
the hippocampus of animals with acute liver failure and acute hyperammonemia indicates the 
involvement of calcium-activated proteolytic enzymes. This could be the result of (early) 
glutamate neurotoxicity; Ii however, there is no evidence of marked neurofilament 
degeneration in this study. Whether these findings are of importance for the pathogenesis of 
hepatic encephalopathy remains uncertain. 
More experimental work on this issue is needed in animal models simulating chronic hepatic 
encephalopathy. However, the results are in agreement with the concept that acute 
encephalopathy due to acute liver failure and acute hyperammonemia is a reversible condition, 
which is not characterized by extensive structural changes in the brain.42 
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Abstract 
Extracellular brain glutamate levels are increased in experimental models of 
acute hyperammonemia and acute liver failure, and glutamate over-exposure may be associated 
with these syndromes. Experiments were perfonned to study the effect of the N-methyl-D-
aspartate glutamate receptor antagonist MK-SOI (dizocilpine) on the development of encepha-
lopathy and survival of rabbits with acute liver failure and acute hyperammonemia. 
MK-SOI (0.05 mglkglhr) or placebo was randomly allocated to 36 rabbits (IS MK-SOI; IS 
placebo) infused with ammonium acetate to induce hyperammonemia simulating that of acute 
liver failure, to IS rabbits (II MK-SOI; 7 placebo) that had undergone a liver devascularisation 
procedure to induce acute liver failure, and to nine control rabbits (4 MK-SOI;5 placebo) 
infused with sodium-potassium acetate. The development of encephalopathy was significantly 
enhanced by MK-SOI (ammonia infusion group: 13.7±6.6 vs. 20±4.3 hours, acute liver failure 
group: 4.2±3.9 vs. 11±2.6 hours); control rabbits treated with MK-SOI also showed signs of 
encephalopathy. Survival was not affected by MK-SOI treatment (ammonium infusion group: 
22.7 ± 5.3 vs. 20.9 ± 4.3 hours; acute liver failure group: 14 ± 7.S vs. 12 ± 2.3 hours, and 
control group: 29.5 ± I vs. 2S.S ± 1.5 hours (MK-SOI vs. placebo)). 
MK-SOI in maximum tolerable dosis did not prevent development of encephalopathy nor 
improved survival of rabbits with acute hyperammonemia and acute liver failure. 
Introduction 
Hepatic encephalopathy (HE) is a neuropsychiatric syndrome in patients with liver 
failure, characterized by disturbance of mental state, neuromuscular signs and electroen-
cephalographic abnormalities. 1 Disturbances in ammonia metabolism are thought to be 
strongly associated with the pathogenesis of HE, although the precise mechanism of ammonia 
toxicity is unknown. Experimental models of acute hyperammonemia or acute liver failure have 
indicated that extracellular brain glutamate levels are increased, H probably as a result of an 
ammonia-induced decrease in glutamate fe-uptake into astrocyte. 4,S Increased post-synaptic 
stimulation by glutamate down-regulates non-NMDA-glutaminergic receptors (kainate and 
AMPA) in experimental acute liver failure, 6 which results in a relative over-exposure of the 
NMDA receptor. 'Over-exposure of the NMDA receptor may lead to increased calcium influx 
intracellularly, disturbance of ion homeostasis, and cellular swelling. Eventually this neurotox-
icity leads to cell death. 7 We hypothesized that glutamate neurotoxicity may have a role in the 
pathogenesis of hepatic encephalopathy. To test this hypothesis, a placebo-controlled experi-
ment was performed to study the effect of blocking NMDA-receptors of rabbits with encepha-
lopathy as a result of acute liver failure and acute hyperammonemia, by treatment with the 
NMDA-receptor antagonist MK-SO I. 
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Animals and methods 
Anima/s. New Zealand white rabbits weighing 2-3 kg were used. Acute hyper-
ammonenlia (AMM) was induced by prolonged intravenous ammonium acetate (NH,Ac) 
infusion. After insertion of a Venfton cannula (diameter 0.8 mm, Viggo, Sweden) into an 
earvein, NH .. Ac was infused at a constant volume of 6 mIlhr, starting with an initial dose of 
0.8 mmollkglhr, which was subsequently increased by 0.2 mmollkglhr every two hours. After 
16 hours the dose remained constant. 8,9 
Acute liver failure (ALF) was induced by a two-stage liver devascularization procedure. 9,10 
Under anesthesia a laparotomy was perfooned: a ligature was placed around the 
hepatoduodenalligament and guided through a plastic tube through the abdominal wall to the 
subcutaneous layer of the left subcostal region, and a small-diameter (5 nilll) side-to-side 
portacaval shunt was constructed. The superior mesenteric artery was clamped to reduce 
splanchnic blood stasis. To correct acidosis after release of the vascular clamps 5 ml 8.4% 
sodium bicarbonate was given intravenously. Postoperatively the rabbits were fed with 
standard laboratory chow and water ad libitum. The second day after the operation, acute liver 
failure was induced by tightening the ligature around the hepatoduodenalligament, after giving 
50 mg amoxicilline intravenously. The rabbits were subsequently placed in a restraining box. 
To prevent hypoglycentia 10% glucose was given intravenously, starting at a volume of3mllhr 
and which was adjusted according to the plasma glucose level when necessary. 
Control rabbits (CON) received a sodium-potassium acetate (NaKAc) solution, which was 
infused, as far as the acetate concentration was concerned, as in the rabbits infused with 
NH,Ac. Blood gasses were measured every 4 hours and blood glucose levels every two hours 
(Haemoglucotest, Boehringer, Germany). Metabolic acidosis was corrected at a blood pH 
levels of7.0, by giving one bolus of 5 ml 8.4% sodium bicarbonate intravenously. 
Study design. A placebo-controlled study was designed; in each experimental group 
animals were treated with MK-80 I or placebo. Two rabbits of one experimental group were 
studied simultaneously. MK-80I or placebo treatment was allocated to each animal by 
randomization, performed by a laboratory analyst who also prepared the syringes containing 
the MK-80I or placebo solution. The study investigators were not aware of which treatment 
was given. The outcome measures were: time needed to develop encephalopathy and survival 
time. Necropsy was performed in all animals to exclude gross morphological abnormalities of 
the lungs and the intestine, and to confirm the tightening of the ligature in the ALF rabbits. 
Immediately after sacrifice or spontaneous death, blood was drawn for bacterial cultures. All 
experiments were approved by the ethical committee on animal experiments of the Erasmus 
University Rotterdam. 
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Study medication. MK-80 I [(+)-5-methyl-IO,II-dihydro-5H-dibenzo(a,d)cyclo-
hepten-5,10-imine maleate] (dizocilpine) was provided by Merck Sharp & Dohme Research 
Laboratories, New Jersey, USA. Results of a dose-finding study with intravenous doses of 
MK-801(ranging from 0.01 to 0.1 mglkglhr) showed increasing side effects from a dose of 
0.05 mglkg/hr (data not shown). Thus, MK-801 was dissolved in 0.9% saline to yield a dosage 
of 0.05 mglkglhr. MK-801 was administered intravenously at a constant volume of 4 mLlhr. 
Placebo treated animals received 4 ml of 0.9% saline/hour. The study medication was 
administered simultaneously with the infusion ofNH,Ac (AMM group), NaKAc (CON group) 
or with the infusion of glucose (ALF group). 
Evaluations. 
Clinical Assessment. During the experiments rabbits were kept in a restraining box and at 
regular time-intervals they were put into a large cage for clinical evaluation. Encephalopathy 
was graded every two hours: stage A: ataxia or disturbance of the righting reflex; the animal is 
not getting up immediately when placed on its side; stage B: absence of righting reflex; the 
animal lays in the cage and cannot come to sitting position, not even after stimulation, and does 
not lift its head. II Rectal body temperature (philips Digital Thermometer, the Netherlands) 
was measured at the start of the experiments and at encephalopathy stage B. Respiratory 
frequency was documented every two hours by observing the animals. Heart rate was 
measured every two hours by stethoscope. 
Biochemical assessment. After insertion ofa Venflon cannula into an ear artery, arterial blood 
samples were taken every two hours for ammonia determination, using the enzymatic method 
according to Da Fonseca. 12 
Spectral analysis of the electroencephalogram (EEQ). Three silver electrodes were implanted 
directly onto the dura for EEG monitoring. Two electrodes were placed onto the right 
hemisphere, one anterior (3 mm) and one posterior (II mm) to the sutura coronaria. The third 
electrode, the ground electrode, was placed onto the left hemisphere. The electrodes were 
fixed onto the skull with dental cement. Automated EEG analysis (spectral analysis) was 
performed as follows 13: during 100 seconds, variations in the electric potentials between 0.53 
and 70 cycles per second in the frontal-occipital lead were registered by an EEG-apparatus 
(Siemens Elema EEG 10, Sweden). The data entered into a personal computer (Olivetti M24, 
Italy). To avoid interference of high frequency energy, signals were filtered at 25.6 Hz. The 
power spectnllll was constructed, lIsing Fast Fourier Transformation, and the mean dominant 
frequency (MDF) was calculated. 
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Statistical allalysis. After closure of the database, the randomization code was broken 
and intention-to-treat analysis was performed. In addition, per protocol analysis was performed 
after exclusion of the following rabbits: CON rabbits that died spontaneously during the 
experiment, AMM rabbits that did not survive for at least 16 hours, and ALF rabbits that did 
not survive for at least 6 hours. In such cases death was considered not to be due to 
encephalopathy, but to postoperative complications or to intercurrent disease. 9 Time needed 
to develop encephalopathy stage A and B and survival time were tested with the Wilcoxon 
rank sum test. Statistical significance denotes p < 0.05. 
Results 
Survival allalysis. A total of 63 animals were enrolled in the study. Nine rabbits in the 
control group (CON), 18 rabbits in the acute liver failure group (ALF) and 36 rabbits in the 
ammonia infusion group (AMM) (table 1). 
Table 1 Survival of rabbits with acute hyperanunonemia and acute liver failure treated 
with MK-80 1 or placebo. 
group animals llun'ival (lit) p-value ll animals survival Cpp) p-valuc .... 
1ft rnean±SD pp mean±SD 
(n) (range) (n) (range) 
CON 
MK-SOI 4 29.5 ± I (2S-30) 4 29.5 ± I (2S-30) 
placebo 5 27.6 ± 2.9 (23-30) 0.27 4 2S.S ± 1.5 (27-30) 0.27 
AMM 
MK-SOI 18 2I.S±6.3 (7-31) 17 22.7 ± 5.3 (12-31) 
placebo IS 20.9±4.3 (14-29) 0.47 18 20.9 ± 4.3 (14-29) 0.29 
ALF 
MK-SOI II 9.6±S.9 (0.5-30) 7 t4 ±7.S (5-2S) 
placebo 7 8.7 ± 5.9 (0.2-15) 0.82 5 12±2.3 (9-15) 0.63 
CON: control animals; AM:M: anunonia infusion; ALF: acute ii\'er failure; itt: intention to treat; pp: per protocol 
analysis. * p-value: Wilcoxon rank sum test, MK-80 1 vs, placebo. 
Intention-to-treat analysis showed no difference in survival in either of the three groups, 
comparing MK-801 treatment with placebo (table 1). For the per protocol analysis, eight rabbits 
were excluded: in the CON group one rabbit died spontaneously after 23 hours. Post-mortem 
examination of the lungs showed signs of pneumonia. In the AMM group one rabbit died 7 hours 
after starting the infusion. Post-mortem examination also showed signs of pneumonia. In the ALF 
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group 6 rabbits died within two hours after tightening of the ligature. Post-mortem examination 
showed signs of intestinal ischemia in one rabbit, severe abdominal bleeding in two, and an 
occluded shunt in one rabbit. Two rabbits in the ALF group died of unknown cause (one was 
randomized to receive MK-801; the other one placebo). In the per protocol analysis, survival of 
animals with acute liver failure was markedly longer than in the intention-to-treat analysis, but 
again in neither of the three experimental groups a difference in survival between MK-801 treated 
animals and placebo was observed. (table I, figure I). 
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Figure 1 Survival after MK·801 or placebo of the three experimental groups. Survival time after MK·801 
treatment of rabbits with encephalopathy as a result of hypcranunonemia and acute liver failure (per 
protocol analysis). Every dot on the graph represents the sttn'ivai time (hours) of one rabbit. X-axis: lvfK: 
MK-80 I treatment; P: placebo treatment; CON: control animals; AM:M: animals infused with ammonia; 
ALF: animals with acute liver failure. Horizontal1ines indicate the median survival time. 
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Clinical alld biochemical evaluatiolls. 
Vital signs. No difference in heart rate, respiratory frequency nor body temperature was found 
between MK-SOI and placebo treated animals (data not shown). 
Development of encephalopathy The results of animals included in the per protocol analysis are 
listed in table 2. CON animals treated with placebo did not show signs of encephalopathy. 
However, CON animals treated with MK-SO I developed encephalopathy stage A after 2.5±1 
hours and stage B after 22.5±S.5 hours. This effect ofMK-SOI explains that also in the AMM 
group the time needed to develop encephalopathy stage A and B, and in the ALF group the 
development of encephalopathy stage B was significantly less in animals treated with MK-SOI, 
compared with placebo. 
Table 2 Development of encephalopathy stage A and B of rabbits with acute 
hyperammonemia and acute liver failure treated with MK-SO I or placebo (per 
protocol analysis) 
group number of 
anlmal!l 
CON 
MK·801 4 
placebo 4 
AMM 
MK·801 14 
placebo 18 
ALF 
MK·801 7 
placebo 5 
sfageA 
2.5± I 
n.d, 
2.2± I 
17.3±4 
1.3 ± 0.5 
5.5±3 
p-value~ 
<0.001 
0.1 
stage B 
22.5 ± 8.5 
n.d. 
13.7 ± 6.6 
20 ± 4.3 
4.2 ± 3.9 
II ± 2.6 
p_value ff 
0.02 
0.05 
CON; control animals; ALF: acute liver failure; AMM: anunonia infusion. Development of encephalopathy expressed in 
hours (mean ± SD) .• p-value: Wilcoxon rank sum test, comparing MK-801 vs. placebo. n.d.: not detected 
Arterial ammonia. The results of animals included in the per protocol analysis are listed in table 3 
and in figure 2. The arterial ammonia concentration increased significantly in both AMM group 
and ALF group, which is in accordance with previous studies, using the same models. 2.g·11 
Baseline arterial anunonia levels of ALF animals were higher, as a result of the portacaval shunt, 
constructed 24 hours before the start of the experiment (96±4S vs. 43±14 f.mol/L 
(mean±SD:p<O.OO I )). 
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Table 3 Arterial ammonia concentrations (~mol!L) at baseline, at encephalopathy stage A and 
B, and shortly before death of rabbits with acute hyperammonemia and acute liver 
failure treated with MK-801 or placebo (per protocol analysis). 
group TO p-value stage A p.nlue stage B p-value Te p-nlue 
CON 
MK-SOI 34±7.S 28±3.4 24±1.7 24±3 
placebo 35±5.7 0.9t n.d. n.d. 26±5 0.67 
AMM 
MK-SOI 42±14 170±55 477±16S 715±101 
placebo 43±14 O.SI 626±IOO <0.01 706±99 0.001 677±146 0.39 
ALF 
MK-SOI S0±23 IS2±I7S 276±9S 321±156 
[!Iacebo 115±64 0.19 241±109 0.59 444±147 O.OS 525±ISS 0.1 
CON: control animals; AMM: anunonia infusion, ALF: acute liver failure. AnmlOoia levels are expressed as mean±SD. 
TO: baseline values; stage A and B: value at encephalopathy stage A and B; Te: values before death. "p-value: unpaired 
Student-t test, comparing MK·801 vs. placebo. n.d.: not detected. 
At encephalopathy stage A both AMM group and the ALF group had similar ammonia 
levels (363±247 vs. 212±140 ~moVI (p~O.I)); at encephalopathy stage B ammonia levels were 
significantly higher in the AMM group, compared with the ALF group (557±183 for AMM vs. 
332±136 ~moVI (p~O.002)). The same difference was found shortly before death of the animals 
(figure 2). The time needed tot develop encephalopathy in AMM rabbits is considerably longer, 
compared with ALF rabbits. Other factors induced by acute liver failure apart from 
hyperammonemia enhance the development of encephalopathy and death. ,·Il 
CON animals treated with MK-80 I had normal arterial ammonia levels at the time of 
development of encephalopathy. AMM rabbits treated with MK-801 developed encephalopathy 
stage A and B at significantly lower arterial ammonia levels, compared with placebo treatment. In 
the ALF group no difference in ammonia levels between MK-801 or placebo treated animals was 
found (table 3). 
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Figure 2 Arterial anunonia levels (IlmollL) of the three experimental groups: MK-801 treated animals and placebo 
treated animals taken togetJler. Line shows mean arterial anunonia levels (pmol1J.)(Y -axis); vertical bars 
indicate mean ± S.E.M. X-axis: 0: baseline values; 4, 8, 12: values after four, eight and twelve hours, 
respectively. Te: values shortly before death. CON: control animals; Alvl1vf: animals infused with 
ammonia; ALF: animals with acute liver failure. 
Spectral analysis of the EEG. 
The mean dominant frequency (MDF) of animals included in the per protocol analysis are 
presented in figure 3. The MDF of CON animals was unaltered during the experiments (figure 
3a). The MDF of AMM animals and of ALF animals was significantly decreased at encepha-
lopathy stage B, compared with baseline (for AMM: 3.4±O.7 vs. 5.0±1.1 Hz: p<O.OOI; for ALF: 
3.0±0.4 vs. 5.6±1.3 Hz: p<O.OOI), which is in accordance with previous studies, using the same 
models. 9.11 The MDF of CON animals treated with MK-SOI was unaltered during development of 
encephalopathy stage B, compared with baseline (3.3±O.7 vs. 3.S±0.4 Hz (mean±SD: p~0.45). 
MDF of AMM animals treated with MK-SOI was significantly decreased shortly before death, 
compared with placebo (2.6±0.4 vs. 3.3±1.I Hz: p~O.04) (figure 3b). No significant difference in 
MDF was found in ALF animals treated with MK-SOI, compared with placebo (figure 3c). 
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Figure 3: Difference in mean dominant frequency (Hz) of the electroencephalogram of the three experimental 
groups. Baseline \'s. stage A and B and shortly before death. MK·801 compared with placebo. Figure 3a: 
conlrol animals (CON); figure 3b: animals infused with anunonia (AM:M); figure 3c: animals with acute 
liver failure (ALF). Lines show mean difference in MOF (Hz)(Y -axis), vertical bars indicate mean ± S.D. 
X-axis: TA-baseline: dilference between MDF at encephalopathy stage A and baseline; TB-baseline: 
difference between MOF at encephalopathy stage B and baseline; Te·baseline: dill'erenee between lvIDF 
shortly before death and baseline. Dotted line: placebo treatment; solid line: MK-801 treatment. CON 
animals treated with placebo did not develop encephalopathy (only solid line given). 
48 
1.2 MK-80J ill hepatic encephalopathy 
Discussion 
Within the conditions of our study, MK-801, an antagonist of the NMDA receptor, does 
not improve survival of rabbits with encephalopathy as a result of acute liver failure or acute 
hyperammonemia. Development of encephalopathy was significantly enhanced in MK-80 1 treated 
rabbits and it developed at lower levels of ammonia, compared with placebo treated rabbits. 
Control rabbits also showed signs of encephalopathy after MK-80 1 infusion. 
Neurologic side-effects of MK-801 have shown to be dose-dependent. "·16 Kochhar et ar.' 
observed slight sedation after an intravenous bolus-injection of 0.2 mg/kg in rabbits, and 
significant side-effects were seen at 0.4 mg/kg: ataxia, loss of righting reflex and sedation were 
evident in 5 minutes after injection. Others observed ataxia, circling and lateral head nodding of 
rats and rabbits after administration of 0.5 mg/kg MK-801 intraperitoneally. ".16 Marcaida et al. 17 
could prevent death of mice and rats with acute hyperammonia through pre-treatment with MK-
801. In this animal model of acute ammonia toxicity, intraperitoneal administration of ammonia 
results in very high ammonia levels within minutes after injection. This rapid increase induces 
convulsions and death of these animals. The observed effect ofMK-801 could be the result of its 
anti-convulsive activity. 1~,16 In our model ammonia increases more slowly - simulating acute liver 
failure - and convulsions are rarely observed in our model. 9,11 
Our results do not give support to the hypothesis that high extracellular brain glutamate playa 
role in the pathogenesis of encephalopathy associated with acute liver failure or acute 
hyperammonemia. However, our results contrast with observations by others: Vogels et al. 18 
found improvement in encephalopathy in rats with acute liver ischemia and ammonia infusion by 
treatment with memantine, also an antagonist of the NMDA receptor. The dose of memantine 
used in that study was high enough to induce the kind of side-effects we found, and which were 
found by others, using the same animal. 16 However, no side-effects were reported in this study. 
This observed difference in tolerability between MK-801 and memantine has also been described 
in other brain disorders. 19 
So, we have to address the reliability of our findings; firstly, the animal models for acute 
hyperammonemia and acute liver failure we used are highly reproducible with respect to arterial 
ammonia levels and to the development of encephalopathy. 9 In these models encephalopathy is 
accompanied by increased extracellular brain glutamate levels. 3 Secondly, the dose of MK-801 
we used was supposed to be high enough to protect neurons from glutamate neurotoxicity. 14,16 
The side-effects observed in all groups during MK-801 treatment indicate that we used an 
effective dose. Thirdly, the placebo-controlled design, the objective elements in the outcome 
measures and the number of animals in each group greatly limits the chance of selection bias or a 
type II error responsible for our negative findings. 
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If glutamate neurotoxicity plays a causal role in the pathogenesis of encephalopathy, blocking of 
the NMDA receptors should reverse encephalopathy and increase survival. Our results do not 
give support to the hypothesis that glutamate neurotoxicity has a major role in the pathogenesis of 
encephalopathy associated with acute hyperammonemia and acute liver failure. 
Encephalopathy sets in more rapidly during MK-80 I treatment in both experimental conditions, 
and especially in AMM rabbits, which was objectified by electroencephalography. This 
observation suggests that decreased glutarnatergic neurotransnUssion rather than glutamate over-
exposure is related to the pathogenesis of hepatic encephalopathy. '~'I 
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Abstract 
Non-thyroidal illness (NT!) is a common finding in patients with chronic liver disease. 
Reports have indicated, that NTI may have a role in the pathogenesis of hepatic encephalopathy. 
To test this hypothesis, thyroid hormones were measured in serum and in cerebrospinal fluid 
(CSF) of dogs with portal-systemic encephalopathy as a result of a portocaval shunt and partial 
hepatectomy. In 9 beagle dogs (5 0', 4 ~, median age 1.5 years, mean weight 11.5 kg) a 
portocaval shunt was constructed (PCS) and a 40 % hepatectomy was performed. 9 pair-fed 
SHAM operated dogs served as controls. At baseline and at four weeks after surgery the severity 
of hepatic encephalopathy was graded, and blood samples were drawn for analysis of ammonia, 
albumin, bile acids, thyroxine (T,), triiodothyronine (T,), free T, (FT,) , reverse T" T,-sulphate 
(T,S), and T,-sulphate (T,S). 
PCS dogs developed clinical signs of encephalopathy, hyperammonemia and hypalbuminemia. T, 
and T,levels decreased significantly, and T,S degradation was significantly diminished. 
Free T" reverse-T, and 13 S levels remained unaltered. In SHAM dogs;r and,T were also 
decreased, which was significant for T4 only. 
Low T, and T, levels reflect altered plasma protein binding, diminished hepatic T, uptake and 
decreased type I iodothyronine deiodinase activity (nI). The changes in T, and T, levels observed 
in SHAM dogs is probably the result of caloric deprivation. 
The contribution of this altered thyroid hormone metabolism to the pathogenesis of portal-
systemic enephalopathy remains speculative. However, T4 uptake into the brain may be 
compromised by the same substances that interfere \vith plasma thyroid homlone binding and with 
T, uptake into the liver. Future research is needed to prove whether altered brain uptake of 
thyroid hormone into the brain is related to hepatic encephalopathy. 
Introduction 
Altered thyroid hormone metabolism is a common finding in patients with chronic liver 
disease. 1,2 Low triiodothyronine (T,) and low thyroxine (T,) levels have been described, without 
clinical signs of hypothyroidism. In general, central regulation of the thyroid gland is preserved 
in patients with chronic liver disease. The observed changes in thyroid hormone metabolism have 
therefore been classified as non-thyroidal illness (NT!). '.' Studies in patients with chronic liver 
disease have indicated, that T4 and T) are sensitive markers for the severity of liver disease. 5,6 
Moreover, a case-control study performed at our department indicated, that serum total T3 has 
strong independent predictive power for hepatic encephalopathy'. A recent case-report 
suggested, that supplementation of thyroid hormone may improve portal-systemic 
encephalopathy. 8 We therefore hypothesize, that NT! has a role in the pathogenesis of hepatic 
encephalopathy. To test this hypothesis, we measured thyroid hormones in serum and in 
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cerebrospinal fluid (CSF) in dogs with portal-systemic encephalopathy as a result of a portocaval 
shunt and partial hepatectomy. 
Animals, materials and methods 
Allimalsalldprocedures. In 9 beagles (5 d', 4 ~, median age 1.5 years, mean weight 1l.5 
kg) an end-to-side portocaval shunt was created and a 40% hepatectomy was performed as 
described before. 9 Each of these dogs (referred to as PCS dogs) was assigned to a control dog 
of the same gender, and approximately the same weight and age. In the control dogs a sham 
operation was performed, consisting of clamping of the portal vein for 10 minutes and 
manipulation of the liver lobes and the structures in the hilar region of the liver (dogs referred to 
as SHAM). All dogs were housed under natural lighting conditions, had free access to water, and 
received a moderately protein-restricted canned dog food (14.7% protein dry matter base; 
KID ", Hill's Pet Nutrition, Topeka, Kansas, USA). The PCS dogs were fed ad libitum twice 
daily. SHAM dogs were pair-fed with the amount offood their partner had eaten the day before. 
Body weight was recorded weekly. Clinical grading of hepatic encephalopathy was performed 
once daily by one observer on an ordinal scale: 0: normal; I: reduced motility andlor mild apathy; 
2: severe apathy andlor mild ataxia; 3: salivation, severe ataxia, head pressing, apparent blindness, 
andlor circling; 4: seizures andlor nearly complete to complete unresponsiveness (coma). 10 
Surgical procedures were performed under sterile conditions and under general anaesthesia 
consisting ofa premedication with 0.3 mUkg ofa mixture ofdroperidol (2.5 mglmL) and fentanil 
(0.05 mglmL) (Thalamonal", Janssen Pharmaceutica, Tilburg, the Netherlands), induction with 
sufentanil (Sufenta", Janssen Pharmaceutica, Tilburg, the Netherlands) 2-2.5 ~g!kg N dosed to 
effect, and maintenance by artificial ventilation with a mixture of isof]urane NzO, and ~ and 
sufentanil 1-1.5 ~glkg IV. The protocol of this study was approved by the Ethical and Animal 
Welfare Committee of the Faculty of Veterinary Medicine of the Utrecht University, and dogs 
were given humane care. 
Samplillg of blood alld cerebrospillal fluid (CSF). Arterial and venous blood samples and 
CSF were collected after a 12 hour fast before and one month after the surgical procedure. The 
arterial samples were placed immediately in sodium-EDTA coated tubes on melting ice. Samples 
were centrifuged at 0_20 C and the plasma anullonia concentration was measured by an enzymatic 
method (Boehringer Mannheim, A1mere, the Netherlands). Venous samples were used for 
determination of plasma albumin and total bile acids with standard laboratory techniques. The 
remainder of these samples was frozen at -70'C until analysis of the thyroid hormones. CSF was 
taken via puncture of the cisterna magna under anaesthesia with prepofol (Rapinovet'~, 
Mallinckrodt Veterinary, Aalst, the Netherlands) 1-3 mglkg IV to effect, and ammonia was 
measured immediately as described above. 
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Determination of serum thyroid hormones. Plasma total T ... T 3 and rT 3 were 
detennined by specific radioimmunoassays, as previously described 11 Plasma free T, was assayed, 
using Amerlite MAB FT, kit (Amersham, Buckinghamshire, UK). Plasma T,S and T,S were 
determined by specific radioimmunoassays essentially as described by Wu 12 and Chopra. 13 
Statistical analysis. Differences in clinical and biochemical parameters were tested with 
the two-sided Wilcoxon matched pairs signed rank sum test (baseline versus four weeks after 
surgery), and Wilcoxon rank sum test (pCS versus SHAM: baseline values and values four weeks 
after surgery). Skewness of data on thyroid hormones, metabolites, and ratios was evaluated with 
the variance ratio test (F test). Differences of samples with equal variances were tested with the 
two sample t test (paired data: baseline versus four weeks after surgery; unpaired data: PCS 
versus SHAM: baseline values and values four weeks after surgery). Differences of skewed data 
were tested with the two-sided Wilcoxon matched pairs signed rank sum test (baseline versus four 
weeks after surgery), and Wilcoxon rank sum test (pCS versus SHAM: baseline values and values 
4 weeks after surgery). Level of significance denotes p < 0.05. 
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Results 
Clinical and biochemical parameters are listed in table 1. pes dogs had severe portal-
systemic shunting, as reflected by a significant increase in bile acids and arterial ammonia. Arterial 
ammonia was significantly increased in pes dogs at four weeks after surgery, compared with 
SHAM dogs (239 ± III vs. 33 ± 12 ~mollL (p~0.002)). The difference in baseline ammonia 
levels and anunonia levels at 4 weeks after sugery against the grade ~f encephalopathy is 
presented in Figure I. eSF anunonia levels were signficantly increased in pes dogs at four weeks 
after surgery, compared with SHAM dogs. Albumin levels were significantly decreased in pes 
dogs at four weeks after surgery (32 ± 2 vs. 26 ± 3.7 gIL: p~0.008). Albu",in levels of pair-fed 
SHAM dogs remained unaltered (table I). 
Body weight decreased significantly in both experimental groups. pes dogs had clinical signs of 
encephalopathy four weeks after surgery, ranging from grade 0-4. One pes dog did not have 
I 
clinical signs of hepatic encephalopathy at the day of sampling. However, several episodes of 
encephalopathy were observed in this dog during the post-operative period, and its biochemical 
profile was similar to the other pes dogs (arterial ammonia increased from 37 to 151 ~mollL, 
eSF ammonia increased from 9 to 78 fimollL, and bile acids increased from 8 to 480 fimoIlL). 
Total thyroxine (T,), triiodothyronine (T,), free thyroxine (FT,), reverse triiodothyronine (rT,), 
T,-sulphate (T,S) and T,-sulphate (T ,S) were similar in both animal groups at baseline (table 2). 
T, and T,levels decreased significantly in the pes group at four weeks after surgery, compared 
with baseline (T,: 19.8 ± 8.8 to 6.6 ± 3.0 (p~0.004); T ,: 1.0 ± 0.28 to 0.28 ± 0.21 (p~0.004)). 
In the SHAM group, T, levels were also significantly decreased at four weeks after surgery. 
However, this decrease in T, was not as pronounced as in the pes dogs (for pes: 6.6 ± 3.0 vs. 
17.6 ± II for SHAM (p~O.OI))(figure 2a, 2b). 
Free T" reverse T ,and the T ,IT ,ratio remained within normal limits in both groups (table 2, 
figure 2c, 2d). T,S was significantly increased in pes dogs at four weeks .. fter surgery, compared 
with SHAM dogs. In accordance with the decrease in T, and unaltered rTllevels, theT,IrT, ratio 
was decreased in the pes group at four weeks afier surgery, compared with SHAM, and the rT 
iT" ratio was increased. The T4 SIT" ratio was significantly increased, and the T3 S/T3 ratio was 
significantly increased in the pes group at four weeks after surgery, compared with SHAM dogs 
(table 2). 
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Table 1 Baseline clinical and biochemical parameters of dogs with a portacaval shunt and partial hepatectomy (peS) 
and sham-operated controls (SHAM), compared with levels at four weeks after surgery. 
pes SHAM p-nlue# 
pes "'So SHAM 
parameter baseline four weeks after p-yalue'" baseline four weeks p-yaIue'" baseline four weeks 
surgery after surgery after surgery 
HE grade 0 I (0 - 4) 0.04 0 0 0.73 1.0 0.02 
arterial NH) (J.UIlOlJ1.) 34± 9.8 239±III 0,004 42± 11 33± 12 0.75 029 0.002 
CSF NH, CfllIloJIL) 4,S ±2.8 96±39 0.13 4.0±2.4 II ±S.2 0.06 0.83 0.003 
albumin (gIL) 32±2.0 26 ± 3.7 O,OOS 30±2.4 2S±2.7 O.IS 0.33 0.09 
bile acids ().UUoI/L) 9± 1.6 228±204 O.OOS 8.3 ± 1.0 21±20 O.1S 0.43 0.002 
body weight (kg) 11.5± 1.8 9.4 ± 1.4 <0.001 11.5± 1.S 10.0±1.5 <0.001 0.49 0.90 
Grade hepatic encephalopathy (HE): median (range); all other parameters: mean;±:SD(n). *p-value: body weight: two sample t test (paired). 
All other parameters: Wilcoxon two-sided matched pairs signed rank sum test: baseline vs. four weeks after surgery. #p-value: body weight: 
two sample t test (unpaired). All other parameters: Wilcoxon rank sum test.: pes vs. SHAM. 
Table 2 Thyroid honnones, ratios and metabolites in serum of dogs with a portacaval shunt and pattial hepatectomy (peS) 
and sham-operated controls (SHAM). Baseline values compared with levels at 4 weeks after surgery. 
pes SHAM p-value# 
pes "~So SHAM 
parameter baseline four weeks after p-value* baseline four weeks p~"alue* bueline four weeks 
surgery after surgery after surgery 
total T4 (runol/L) 19.8±8.8 6.6±3.0 0.004 24.3±10.3 17.6 ±I 1.0 0.04 0.37 om 
total T3 (runol/L) 1.0±0.28 0.28±O.21 0.004 l.l±O.20 0.6I±O.32 0.29 0.29 0.02 
free T4 (pmol/L) 17.7±72 18.5±4.3 0.70 21.7±7.4 18.4±4.5 039 0.26 0.97 
reverse T3 (pmoIIL) 0.6±O.19 0.49±O.l5 0.13 0.6±O.16 0.56±O.20 0.36 0.97 0.46 
T4 sulphate (pmol/L) 162±58 253±106 0.Q2 199±59 2S1±132 0.67 0.22 0.96 
T3 sulphate (pmollL) 364±124 305±164 0.46 413±136 276±102 0.13 0.45 0.68 
T,/T4 fatio 0.05±O.02 0.OS±O.03 0.30 0.05±O.02 0.04±0.03 0.49 0.56 0.88 
T)/rT3mtio 1.9±O.78 0.53±O.28 0.002 2.0±0.40 I.S±O.99 0.45 0.72 0.01 
rT3/T4 ratio 0.03±O.01 0.ll±O.09 0.04 0.03±O.01 0.04±0.02 0.69 0.21 0.08 
T4S/T4 ratio 8.7±3.3 53±37.0 0.004 8.7±3.1 14.6±9.9 0.22 0.96 om 
T3S/T,ratio 348±89 1649±1709 0.004 381±162 487±238 1.0 0.92 0.003 
"'p~va1ue: total 1'4. total T 3' T 4SfT4 ratio and T3Srr ,ratio: two-sided Wilcoxon matched pairs signed rank Stun test; all other parameters: two sample t test (paired).: 
baseline VS. four weeks after surgery. #p~value: total T,. T4S!f4ratio and T,S!T,ratio: Wilcoxon rank sum test: all other parameters: two sample t test (unpaired): 
pes vs. SHAM. 
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pes SHAM 
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Figure 2a and 2b: 
T4wk TO T4wk 
T4 1evels and TJlevels afPeS and SHAM dogs. Baseline values, compared with values at 
fOUIweeks. Left graph: pes dogs, right graph: SHAM dogs. X-axis: TO: baseline values; 
T4 wk: le\'eis at four weeks. Y -axis: T~ and T3 Ievels, expressed in nmollL. 
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PCS SHAM 
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Figure 2c and 2d: T)ff4 ratio and free T. levelsofPCS and SHAM dogs. Baseline values, compared with 
values at four weeks. Left graph: PCS dogs, right graph: SHAM dogs. X-axis: TO: baseline 
values; T4 wk: levels at four weeks. Y-axis: free T4 levels, expressed in pmollL. 
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Discussion 
Total T, and T, levels were significantly decreased in dogs with a portocaval shunt and 
a 40% hepatectomy. Free T, remained unaltered four weeks after surgery, indicating that 
euthyroidism is maintained in serum. In pair-fed SHAM operated dogs, total T, and T, levels 
decreased at four weeks after surgery, which was significant for T, only. 
How can we explain our results? 
Low T,and T, and normal free T , levels indicate decreased plasma protein binding ofT, and T 
,Decreased plasma binding could be the result of decreased hepatic synthesis of thyroid binding 
proteins. 1,2 Although thyroid binding proteins were not measured in this study, a decrease in 
cortisol binding protein has been described in the same animal model. 14 In addition, presence 
of hypalbuminemia and the partial hepatectomy ofpCS dogs supports the notion of diminished 
hepatic protein synthesis. Moreover, competitive inhibitors of plasma protein binding may have 
contributed to the low T, and T,levels. " 
The liver is the major site of extra-thyroidal T, production. In humans, 80 % o~ T is 
synthesized in the liver from T •. 16 Firstly, the low plasma T, levels found in PCS dogs could be 
explained by decreased hepatic synthesis by type 1 iodothyronine deiodinase (Dl). Sulphated T, 
and T, (T,S and T, S) are high affinity substrates for Dl, making them sensitive markers for 
hepaticDl activily(l7). Presence of increased levels ofT,S in PCS dogs in addition to increased 
ratios ofT,SfT, and T,SfT, all indicate diminished hepatic Dl activity. 
Secondly, low plasma T, levels could be the result of diminished uptake of its precursor T, into 
hepatocytes. Decreased hepatic uptake ofT, has been described in patients with liver cirrhosis 
2, and in other non-thyroidal illnesses and caloric deprivation. 19·21 Specific inhibitors of serum 
binding ofT, and T, may also compete with T, uptake into hepatocytes. Compounds with these 
inhibitory properties include: bilirubin, nonesterified fatty acids, 3-carboxy-4-propyl-2-furan 
propanoic acid (CMPF), indoxyl sulphate and L-amino acids. 16.17 Substances that inhibit hepatic 
uptake ofT, may also compromise brain uptake ofT,. For example, L-amino acids have shown 
to competitively inhibit uptake ofT, into mouse neuroblastoma cells. " 
SHAM dogs also showed a significant decrease in T, and a trend towards a decrease in T, levels 
at four weeks after surgery. As body weight is decreasing significantly also in the SHAM group, 
this finding is probably the result of caloric deprivation after pair-feeding. 19·21 
How reliable are our findings? 
The animal model we used is a higl~y reproducible model for chronic liver disease. As a result of 
the induction of a portal-systemic shunt in combination with a 40 % reduction in liver cell mass, 
dogs develop hypalbuminemia, hyperammonemia and clinical signs of hepatic encephalopathy 
within four weeks after surgery. 9 
Our study indicates, that portal-systemic encephalopathy is accompanied by low T, and T, levels 
and normal free T." which is comparable to findings in humans with chronic liver disease. 2,3 
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Probably, these alterations in thyroid hormone metabolism reflect the severity of liver disease and 
caloric deprivation, like in human non-thyroidal illness. The contribution of altered thyroid 
hormone metabolism to the pathogenesis of portal-systemic enephalopathy remains speculative. 
However, T, uptake into the brain may be compromised by the same substances that interfere with 
plasma thyroid hormone binding and with T, uptake into the liver. Future research is needed to 
prove whether altered brain uptake if thyroid hormone into the brain is related to hepatic 
encephalopathy. 
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Abstract 
The efficacy of the benzodiazepine antagonist flumazenil has been assessed clinically 
in a double blind, randomized, placebo-controlled multicentre study in patients with grade I-III 
portal-systemic encephalopathy. In an ancillary study reported here the effect of flumazenil on the 
electroencephalogram (EEG) was analysed in 32 patients who had EEG-grading according to 
protocol. Following the baseline observation period, patients were randomized to receive (at one 
minute interval) three sequential bolus injections offlumazenil (0.4, 0.8 and 1 mg) or placebo, 
foUowed by infusions offlumazenil (1 mglhr) or placebo for 3 hours. Patients were monitored for 
5 hours after infusion. A positive response was defined as 1 point improvement in EEG grade. 
After independent analysis ofthe EEG gradings five out of 17 (29%) flumazenil treated patients 
showed an improvement in EEG-grading (3 after bolus, two during follow-up) compared to two 
out of 15 (13%) placebo treated patients (1 after bolus and during follow-up, I during follow-up) 
(95% confidence interval of difference: -12% to + 50 %). Of the five EEG-responders after 
flumazenil, three also had an improvement in clinical PSE grading (none after bolus, two during 
infusion, one during follow-up), compared to neither of the two EEG-responders after placebo. 
EEG responders did not differ from non-responders with respect to Child-Pugh score, basal EEG, 
PSE grade and positivity for benzodiazepines. In conclusion, treatment perspectives for flumazenil 
in portal-systemic encephalopathy appear to be present for only a minority of patients; however, 
this study yield no support for a major role of benzodiazepine antagonists in the treatment of 
hepatic encephalopathy. 
Introduction 
Flumazenil is an imidazobenzodiazepine, which has a high affinity for the benzodiaze-
pine receptor. Flumazenil blocks the central effects of substances that act via the benzodiazepine 
receptor by competitive inhibition. 1 Intravenous administration of flumazenil promptly reverses 
the hypnotic-sedative effects of benzodiazepines. 2 Since altered GABA-benzodiazepine 
neurotransmission and endogenous benzodiazepine-like substances have been implicated in the 
pathogenesis of portal-systemic encephalopathy (PSE), 3.4.S flumazenil has been evaluated in open. 
~i1 and double blind "." clinical studies. Most studies indicate an effect offlumazenil on clinical 
grades ofPSE. The results of an international multicentre study to evaluate the acute efTects of 
intravenous flumazenil on PSE in a group of patients carefully screened negative for 
benzodiazepine in blood and urine, a positive effect on the clinical PSE grade was observed. 15 
We acknowledge the small effect on clinical PSE grading in four double-blind studies, but consider 
electrophysiologic slowing of brain function a key feature ofPSE. Therefore, we performed an 
anciUary analysis ofEEG readings of patients who had these measurements done according to the 
protocol. 
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Patients and methods 
Patiellts 
Fillmazellil ill hepatic encephalopathy 
A total of 49 patients were enrolled and 28 were randomized to the flumazenil group and 
21 to the placebo group. In this ancillary study we analysed all patients with complete EEG 
readings in the intent-to-treat analysis: 32 of 49 patients initially enrolled in the multi-centre trial 
were analysed (17 in the flumazenil and 15 in the placebo group). 
Only patients with portal-systemic encephalopathy due to chronic liver failure entered the study. 
Patients with acute hepatic failure, coma (PSE, stage IV), encephalopathy other than due to liver 
failure, severe gastrointestinal bleeding, acute hepatitis superimposed on cirrhosis, Wilson's disease, 
hemochromatosis, severe cerebral atrophy (as assessed by cranial Computer Aided Tomography), 
any psychiatric disease except PSE as well as patients receiving psychotropic medication were 
excluded from the study. The severity of liver disease was assessed by the Child-Pugh score. 16 
Study design 
The duration ofthe study was 12 hours. It consisted ofa four hour baseline observation 
period, a three hour double blind treatment period and a five hour follow-up period. Following the 
baseline observation period, patients were randomized to receive (at one minute intervals) three 
sequential bolus injections offlumazenil (0.4, 0.8, I mg) or placebo, after which patients received 
intravenous infusions of either flumazenil (1 mglhr) or placebo for three hours. No concomitant 
therapy was pemlitted during the baseline and double-blind treatment periods, with the exception 
of saline and/or glucose, lactulose, potassium and vitamin K. During the post-treatment 
observation period standard PSE treatment (e.g. antibiotics) was allowed according to the patient's 
condition. Randomisation was performed according to a computer-generated randomisation list 
produced by F. Hoffmann-La Roche Ltd, and according to Roche's Standard Operational 
Procedures. Each clinician and study director received a sealed envelope corresponding to each 
patient, containing the identity of drug administered to that patient. The double-blind code was 
broken only after final data cleaning had taken place and after the database had been locked. 
Evaluations 
The EEG was recorded continuously during the first and the last 20 minutes of the 
baseline observation period and the double blind period. In the follow-up period EEG was recorded 
twice within the first two hours. Clinical experience with flumazenil (when used as a reversal agent 
for exogenously administered benzodiazepines) has shown that its onset of action is generally very 
rapid '. For this reason EEG-gradings were separately analysed comparing the baseline grading 
(the mean of two recording periods) with the EEG-grading inunediately after the bolus injection 
and the EEG-grading after the end of the infusion period. 
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To evaluate late effects offlumazenil therapy (as suggested by others "), we also compared 
the baseline EEG grading with the EEG grading from the follow-up period (mean of two 
recordings). EEG-grading was performed using subscores obtained by visual inspection. 17 EEG 
grading by visual inspection was performed by one experienced investigator, using the following 
modification (developed by Scollo-Lavizzari): grade 0: 8-12 sec basic rhythm, mean dominant 
frequency (MDF) > 8 sec, % theta <20; grade I: sudden shifts between a normal alpha frequency 
(around 9-10 sec) and slow substitutes (6-8 sec); MDF >7 sec, % theta >35; grade 2: diffuse slow 
activity posterior alpha rhythm seen occasionally, MDF 5-7 sec, % theta> 60; grade 3: dominant 
slow activity in all areas, MDF 3-5 sec, % delta 70; grade 4: bilaterally synchronous, 2 to 3 per 
second waves, predominating over frontal lobes and spreading backwards to occipital lobes; 
occasional short-lived appearence offaster rhythms (5 to 6 per second) or voltage depression, 
MDF < 3 sec, % delta 70. In three flumazenil treated patients and four placebo treated patients (all 
from one center) the EEG was also graded by automated EEG analysis; 18.19 the results of both 
gradings were identical. A positive response was defined as I point improvement in EEG-grading 
during treatment or follow-up, compared with the baseline period. 
Clinical PSE grading (comprising disorder of sleep pattern (anamnestic), level of consciousness: 
drowsiness (including mood disorder, inappropriate behaviour. orientation, mental task) , 
somnolence, stupor and coma 20.") was performed at 60-minute intervals during the baseline and 
post-treatment periods and every 30 minutes during treatment, the first assessment taking place 
within five minutes of the bolus injections. A positive response was defined as a twoMpoint 
improvement in clinical PSE grading any time during treatment or follow-up, compared with the 
baseline period. 
Statistical al/alysis 
Demographic and clinical data between flumazenil and placebo treated patients were 
compared using the Fisher exact test (sex and Child-Pugh score) and Student-t test (age, basal 
EEG and PSE grade). Mean improvement in EEG grading was analysed using Wilcoxon rank sum 
test and the percentage improvement in EEG grading was tested, using Fisher exact test, 
comparing the flumazenil treated patients with placebo treated patients. 
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Results 
Demographic and clinical data (age, sex, basal EEG grade, basal PSE grade and Child-
Pugh score) are presented in table 1. These data were not statistically different. The percentage, 
mean and median improvement in EEG-grading was calculated as indicated in table 2. Figure 1 
graphically presents the percentage improvement in EEG grading and the 95 % confidence interval 
of the difference between the flumazenil and placebo treated group. 
Table 1 Demographic and clinical data on flumazenil and placebo group 
Flumazcnil Placebo 
(n=l7) (n=15) p·vslue 
Age mean (sd) 53.4 ± ID.I 51.5±9.3 0.76* 
median (range) 57 (32 - 69) 56 (33 - 66) 
Sex male 15 9 0.15** 
female 2 6 
Basal EEG grade mean (sd) 3.00 ±1.0 2.65 ± 1.07 0.36* 
median (range) 3.25 (0.50 -4.00) 3.00 (0.75-4.00) 
Basal PSE grade mean (sd) 6.76±2.97 7.27± 4.36 0.71* 
median (range) 5.0 (4.0-12.5) 5.0 (3.0-14) 
Child·Pugh score A 
B/C 16 14 0.85** 
Data are presented as mean±SD and median with range. *p-value: student-! test; **p-value: fisher exact test 
The analysis showed an improvement in 5 out of 17 patients (29%) in the flumazenil 
treated group and 2 out 15 (13%) in the placebo treated group. In the Ilumazenil treated group 3 
out of5 patients had an improvement in EEG-grade immediately afler bolus injection and the other 
2 patients improved during follow-up. Three of them also showed an improvement in PSE score, 
2 during the infusion period and one during follow-up. In the placebo treated group two patients 
had an improvement in EEG-grade: one patient improved after bolus injection and during follow-
up (after a deterioration during infusion); the other patient improved during follow-up. None of 
them improved with respect to their PSE score (table 3). 
EEG-responders and non-responders do not differ with respect to their Child-Pugh score, basal 
EEG and basal PSE grading (data not shown). Although there appears to be a trend for a 
flumazenil effect, the results show no significant difference in effect at any time during the study 
between control patients and flumazenil treated patients. At the end oftreatment the difference in 
percentage of response was 16% with a 95% confidence interval of -12% to 50 %. 
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Table 2 Improvement in EEG grading during and after therapy 
FlumazeniJ Placebo 
(n=17) (n=15) p-nlue 
baseline EEG vs. EEG after bolus % (n) 18 (3) 7 (I) 1.0* 
mean (SEM) 0.35 (0.59) 0.25 (0.46) 
median (range) 0(-0.75 - 1.5) 0(-0.5 - I) 0.38 
baseline EEG VS. EEG after infusion % (n) 18 (3) 0(0) 0.23 
mean (SEM) 0.35 (0.78) 0.05 (0.37) 
median (range) 0(-0.5 - 0.75) 0(-0.75 - 2) 0.27 
baseline EEG vs, EEG after follow-up % (n) 29 (5) 13 (2) 0.40 
mean (SEM) 0.38 (0.91) 0.22 (0.48) 
median (range) 0(-0.75 - 2) 0(-0.5-1) 0.29 
Baseline period comprises two separate EEG recording periods (both gradings averaged); after bolus injection and after 
infusion period one EEG recording was made; the follow-up period also comprises two EEG recordings (both gradings 
averaged). *p-value: Fisher exact tcst; all other p-values: Wilcoxon rank sum tcst. 
Discussion 
The results of the double-blind placebo-controlled international multicentre study on the 
effect offlumazenil on clinical grades of portal-systemic encephalopathy (PSE) have recently been 
reported. IS Clinical PSE grading is emerging as the standard method for evaluation of 
encephalopathy. However, since the components of the PSE index are changing 20, the PSE index 
should be validated. In other studies on flumazenil in hepatic encephalopathy. 7,10.12·14 EEG 
recording was included in the efficacy evaluation and the changes in clinical status after flumazenil 
therapy were reflected in the EEG in most patients. Moreover, in one study 13 early effects of 
flumazenil therapy on the cerebral status were evident before clinical improvement could be 
substantiated. EEG grading by spectral analysis is an objective and accurate method to measure 
the degree of electrophysiological slowing in patients with hepatic encephalopathy. 18,19,20 EEG 
gradings based on standard recordings and assessed by one experienced observer yields results of 
equivalent reliability, as EEG by spectral analysis. 21 This ancillary study documents the EEG 
findings of the flumazenil international multicentre study IS and combines these with the results of 
clinical PSE grading. The EEG recordings showed no significant effect of flumazenil on the grade 
of hepatic encephalopathy, although there was a trend due to an effect in a small group of patients. 
A strong point for a flumazenil effect in a subgroup of patients is that 3 out of 5 responders also 
showed an improvement in PSE score. In addition, three flumazenil responders showed an EEG 
improvement just after bolus injection. 
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Table 3 
Flumazenll 
EEG 
PSE 
Placebo 
EEG 
PSE 
Flumazenilll1 hepatic encephalopathy 
Improvement in EEG grading compared to clinical PSE score in patients 
treated with flumazenil and placebo 
baseline treatment follow-up 
bolus iJlfluion 
4 3 2 2 
2 I 0 0 
4 4 4 2 
3 3 3 2 
3 2 2 2 
II II 10 10 
4 4 I I 
5 5 5 I 
8 8 8 9 
4 3 0 0 
4 4 4 3 
3 2 3 2 
12 II II II 
4 4 4 4 
Baseline: the average oftwo EEG recording periods and the average of the first and last PSE score; bolus: EEGIPSE just 
after bolus injection; infusion: EEG/PSE after the end of the infusion period; follow-up: the average of two EEG fec<lrding 
periods and the average of the first and last PSE score. 
How reliable are our findings? No doubt the number of patients in the study was too small for an 
answer with a small confidence interval. In practice, it turned out that several centers had great 
difficulty to register EEG in an appropriate manner at times outside normal office-hours. In view 
of the low recruitment, it was decided that the EEG was no longer mandatory as originally planned, 
but only optional. Therefore only 32 patients from the recruited 49 patients got complete EEG 
recordings; this number was less than the planned total sample size of 40 patients. The power of 
the study might therefore be insufficient to show efficacy based on EEG alone. Other factors which 
may affect the outcome are the methods of recording EEG's, the multicentre nature of the study 
and the fact that the analysis was by intent-to-treat and not matched by a per-protocol analysis. The 
outcome of this study is, however, in agreement with the 4 double blind placebo controlled studies 
reporting a clinical effect offlumazenil in a small proportions of patients. 12-IS 
How to explain the effect offlumazenil in a small proportion of patients? Reversal of the effect of 
endogenous benzodiazepine has been suggested. 4,23 Recent work on the levels ofbenzodiazepines 
in cirrhosis without or with encephalopathy in comparison to exogenous benzodiazepine users, 
however, suggest that endogenous levels ofbenzodiazepine in cirrhosis with encephalopathy are 
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far below levels observed in exogenous drug users without encephalopathy. "Therefore, it 
remains possible that the effect of flumazenil should be explained by reversal of an inapparent 
exogenous benzodiazepine with a long half life. Slowing of electro physiologic brain activity - as 
measured by EEG - is a key characteristic of all patients with portal-systemic encephalopathy. 
Since the effect of flumazenil on EEG is limited to a minority of patients, this study yields no 
support for a major role of benzodiazepine antagonists in the pathogenesis of hepatic 
encephalopathy. In addition, these findings indicate, that activated benzodiazepine 
neurotransmission is of no major relevance to the pathogenesis of hepatic encephalopathy. Other 
studies in animals without potential contamination by exogenous benzodiazepine have come to a 
similar conclusion. 25,26 
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Abstract 
Two decades ago worsening of the electroenecephalogram (EEG) was reported in 
cirrhotic patients after meals. In addition, patients with subclinical hepatic encephalopathy 
sometimes report functional impairments in the second part of the day. Therefore, 12 hour 
portable EEG registration and repetitive analysis of the EEG was performed in patients with 
cirrhosis to evaluate the variability in electrophysiologic slowing and the effect of meals and 
physical exercise. EEG recordings were also graded by visual inspection. 
Twenty-seven patients (5 without encephalopathy; 12 with subclinical hepatic encephalopathy 
(SHE); 10 with clinically manifest hepatic encephalopathy (HE» formed the study group. The 
mean dominant frequency (MDF) was 8.2 Hz (95 % CI: 7.0 - 9.3) for patients without 
encephalopathy, 7.4 Hz (6.9 - 7.9) for patients with subclinical hepatic encephalopathy, and 4.9 
Hz (4.1 - 5.6) for those with clinically manifest encephalopathy. Percentage theta was 17.4 (95 
% CI: 10.6 - 24.2), 38.4 (29.6 - 47.2) and 33.2 (26.9 - 39.5), respectively. No significant 
differences in :MDF and percentage theta activity were observed during the morning, after lunch, 
after exercise, Of after ditmer. On the basis of visual inspection slowing of the EEG was observed 
after lunch in 83 % of patients with subclinical hepatic encephalopathy and in 50 % of patients 
with clinically manifest HE. We conclude that assessment of patients with cirrhosis for hepatic 
encephalopathy by EEG is hardly influenced by time ofthe day, meals or exercise, when assessed 
by mean dominant frequency and percentage theta activity. EEG grading by visual inspection 
appears a more sensitive method to detect variability in electrophysiologic slowing; however, 
changes in consciousness during the day reported by patients with cirrhosis rather reflect 
physiological variability than aggravation of hepatic encephalopathy. 
Introduction 
The clinical syndrome of hepatic encephalopathy (HE) is characterized by disturbance of 
mental state and neuromuscular function. In clinical practice, hepatic encephalopathy is classified 
in four grades. I Slowing of the electroencephalogram (EEG) correlates well with the clinical 
degree of hepatic encephalopathy. "Slowing of the EEG has also been observed in about 20 % 
of cirrhotic patients without clinical signs of hepatic encephalopathy; these patients are defined 
as having subclinical hepatic encephalopathy (SHE). ' 
Patients with SHE often report functional impairments, which appear to be related to certain 
periods of the day (e.g. after a hot meal, physical exercise). ' About two decades ago slowing of 
the EEG was observed in cirrhotics after a meal, independent of the protein content. 6 In routine 
clinical care, automated EEG analysis is performed at random hours during the day. Therefore, 
to evaluate the variability of the EEG during the day and the effect of meals and physical exercise, 
we performed an observational study, using 12 hour portable EEG registration and repetitive 
analysis of the EEG in patients with cirrhosis. 
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Patients and methods 
Subjects 
From January 1995 to May 1, 1997 twenty-seven patients from the department of 
Hepatogastro- enterology of the University Hospital Rotterdam participated in the study. 
Inclusion criteria were: histologically proven cirrhosis of the liver, age between 16 and 80 years 
and written infonned consent. Exclusion criteria were: unstable liver disease (e.g. active variceal 
bleeding, or severe clinical hepatic encephalopathy (grade 3 to 4), history of recent (less than 6 
weeks) alcohol abuse, use of benzodiazepines, anti-epileptics, or other psychotropic drugs, 
inability to perfoml the psychometric tests (due to insufficient knowledge ofthe Dutch language 
or bad vision), and severe medical problems such as congestive heart failure, pulmonary disease, 
etc. that may influence the clinical and e1ectrophysiological assessment of hepatic encephalopathy. 
Assessment 
Categorizing patients. Methods used for categorizing patients with clinically manifest hepatic 
encephalopathy, subclinical hepatic encephalopathy (SHE) and no enephalopathy have been 
described in detail elsewhere. 3·" Clinically manifest hepatic encephalopathy (HE) was assumed 
to be present if at least 2 of the following abnormalities were detected: inverted sleep pattern, 
impaired calculation, disturbed memory, and slowness of speech, or one abnormality in 
association with a flapping tremor. 8 Subclinical hepatic encephalopathy (SHE) was defined, as 
the presence of abnormal slowing of the EEG andlor at least one abnormal psychometric test: 
Number Connection Test part A (NCT-A) or Digit Symbol Test (DST). ' 
The day before the experiment the severity of the liver disease was assessed using the Child-Pugh 
score. 7 Arterial ammonia levels were measured at screening (the day before the experiment) and 
on the morning of the day of the experiment. The mean of both measurements was used in the 
final analysis. 
Electroencephalography. Between 8.00 and 9.00 AM of the day of the experiment, electrodes 
were attached to the skin, and leads TJ-OI, T4-02, CO-OI, CO-02, F4-C4, C4-P4, F3-C3 and 
C3-P3 were recorded. 9 Electrode impedance was kept lower than Sill. At regular intervals of 
30 minutes and 60 minutes, the patient was asked to lay comfortably in his bed with his eyes 
closed. Periods of 120 seconds were subsequently marked on the portable EEG recorder. After 
completion ofthe 12 hour EEG recording, all marked periods were visually checked by an EEG 
technician to evaluate the technical quality. Artefact free recordings were selected and spectral 
analysis of leads TJ-O 1, T4-02, CO-O 1 and CO-02 was performed. After applying the usual 
bandpass filters (0.53 - 35 Hz) recordings of 100 seconds each entered into a computer. 
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After AD conversion (sample frequency 102.4 Hz), ten epochs of 10 seconds each were analysed 
by applying Fast Fourier Transformation and the power spectrum was calculated, with expression 
ofthe mean dominant frequency (MDF) and the relative theta activity. 3 
The EEG tracings used for spectral analysis were printed and graded by visual inspection by two 
expert neurophysologists (authors 1M and MS-B), using the criteria of Parsons-Smith et al. 2 
Worsening of the EEG was defined present, if the EEG grade increased with at least one grade. 
The chronological order of the EEG recordings was changed before visual inspection, and the 
neurophysiologists were blinded for the spectral analysis results and for the clinical grade of the 
patient. Both neurophysiologists compared their gradings afterwards, and a final grading was 
given. 
Dala analysis alld statistics 
Patients included in the study were devided into three groups, on the basis of the 
screening the day before the experiment: group A: patients without HE; group B: patients with 
SHE; group C: patients with clinically manifest HE. 
On the basis of spectral analysis of the EEG the mean dominant frequency (MDF) and percentage 
. theta waves were calculated at the following time points: baseline (10:00 AM); two hours after 
baseline (at noon), lunch (at 2.00 PM), physical exercise (at 4.30 PM) and dinner (at 6.00 PM). 
On the basis of visual inspection, the severity cfHE was graded at the same time points. 
The mean MDF and percentage theta waves was calculated for each group separately, and 
equality of medians between baseline values and each of the time points was tested with the 
Wilcoxon matched-pairs signed-ranks test. The mean difference of the MDF and of the 
percentage theta activity between baseline and each of the other time points was calculated. The 
null hypothesis that each median difference equals zero was tested with the Wilcoxon matched-
pairs signed-ranks test. 
80 
2.1 J 2 hour EEG ill hepatic encephalopathy 
Results 
Baseline parameters are listed in table 1. Five patients without HE, twelve 
patients with SHE and ten patients with clinically manifest HE entered the study. Marked 
differences in age, sex, etiology of liver disease, or dietary protein content were not observed 
between the 3 patient groups, although they differed in the severity of liver disease, as reflected 
by the Child-Pugh score (percentage of patients with Child-Pugh B/C cirrhosis in group A: 60 
%, group B: 75 %; group C: 100 %) and arterial ammonia levels. 
In figure la the mean dominant frequency (MDF) is presented. The MDF was 8.2 Hz (95 % CI: 
7.0 - 9.3) for patients without HE, 7.4 Hz (6.9 -7.9) for patients with SHE, and 4.9 Hz (4.1 -
5.6) for those with clinically manifest HE. In figure Ib the difference in MDF between baseline 
and the other four time points is presented. 
Table 1 Baseline Parameters of patients without HE, patients with SHE and patients with 
clinically manifest HE. 
parameter 
age (median [range]) 
sex (n) 
etiology (n) 
Child-Pugh soore (n) 
arterial anunonia (JL010IiL) 
(mean ± SD) 
dietary protein (gr124 hrs) 
(mean±SD) 
male 
female 
viral 
alcohol 
other 
A 
BiC 
no HE 
(n:5) 
55 (44 - 58) 
4 
3 
2 
0 
2 
3 
70±27 
104 ± 24 
81 
SHE HE 
(n:12) (n:l0) 
50 (29 - 68) 61 (35 -75) 
7 8 
5 2 
3 3 
3 4 
6 3 
3 0 
9 10 
88±22 113±45 
80±23 75± 15 
2.1 
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The results indicate, that there is a trend towards a decrease in MDF during the day. However, 
the mean difference was below zero only after dillller in patients with SHE ( -0.31 (-0.57 - -0.04) 
(p~0.04», considered not statistically significant in view of multiple testing. In patients with 
clinically manifest HE the decrease in MDF is largest after lunch, tlus was also not statistically 
significance. 
In figure 2a the percentage theta waves is presented; the percentage theta was 17.4 (95 % CI: 
10.6 - 24.2) for patients without HE, 38.4 (29.6 - 47.2) for patients with SHE and 33.2 (26.9-
39.5) for those with clinically malufest HE, respectively. No statistically significant changes were 
found during the day. In figure 2b the difference in percentage theta waves between baseline and 
the four time points is presented. 
Figure 2. 
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without HE, patients with SHE and patients with clinically manifest HE. Baseline value versus values 
at noon, aftcr lunch, exercise and after dinner, respectively. X-axis: I: baseline value; 2: value at 
12:00 (noon); 3: value after hutch (2:00 PM); 4: value after exercise (4.30 PM); 5: value after dinner 
(6:00 PM). Y-axis: mean dominant frequency in Hz ± 95 % confidence interval ofmcan difference. 
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Table 2 shows the number of patients in each group with worsening of the EEG by visual 
inspection. On the basis of visual inspection of the EEG, worsening of the EEG was observed 
after lunch in 83 % of patients with SHE and in 50 % of patients with clinically manifest HE. EEG 
glade reverted to baseline in the majority of patients. However, in 4 out of 10 patients with SHE, 
and in 2 out of 5 patients with clinically manifest HE slowing of the EEG remained present 
throughout the afternoon; no additional slowing of the EEG was observed in these patients after 
exercise or after dinner. 
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Worsening ofEEG tracings by visual inspection of patients without HE 
(A), patients with SHE (B) and patients with clinically manifest HE (C) 
at entry. 
worsening or EEG (n (%» 
baseline - baseline - baseline - baseline -
12:00 2:00PM 4:30PM 6:00PM 
HE by vl!!ual inspection (n I %) 
no HE (n"5) 1(20%) 0(0%) 1(10 %) I (10 %) 
SHE (n"12) 3 (25 %) 10 (83 %) 4 (30 %) 4 (30 %) 
HE (n"lO) 1(10%) 5 (50 %) 2 (20 %) 3 (30 %) 
Discussion 
Continuous electroencephalography in patients with cirrhosis showed no significant 
slowing of the EEG during the day, when assessed by the mean dominant frequency and 
percenlage theta waves; on the basis of visual inspectiol\ worsening of the EEG grade after lunch 
was observed in patients with SHE and HE. 
OUf findings indicate, that grading by visual inspection is a more sensitive method to detect 
electrophysiologic slowing during the day. The changes apparently are subtle as they are not 
reflected in significant variability in MDF nor in percentage theta waves, when assessed by 
spectral analysis. The high sensitivity of subjective grading by visual inspection ofthe EEG may 
have influenced the results of past studies on prolonged EEG recordings. 6 
We used the method of spectral analysis of the EEG, which was validated in our department 
more than 10 years ago as an objective tool to quantity e1ectrophysiologic slowing in hepatic 
encephalopathy. 3.4,10 
The method yields erroneous results if insufficient attention is given to technical aspects and 
interfering artefacts; if technical adequate tracings are analyzed results are reproducible and 
congruent to grading by visual inspection. 10 Furthermore, we assessed the variability of the over 
time in three groups of patients with varying grades of encephalopathy, and our results fit those 
reported by others. II 
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What are the implications of this study? 
Since we adhere greater importance to changes in MDF and percentage theta waves than to 
subtle changes detected by visual inspection, we think that changes in conscioussness during the 
day reported by patients with cirrhosis are within the physiological range and not aggravation of 
hepatic encephalopathy by meals or exercise. Our results also imply that assessment of hepatic 
encephalopathy can be done at random hours during the day. 
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Abstract 
Subclinical hepatic encephalopathy (SHE) is assumed to have a negative effect on 
patients' daily fimctioning, therefore treatment is reconunended. However, no studies have 
been perfonned that document the clinical relevance of SHE. We perfonned a study in which 
the prevalence of SHE was determined in 179 outpatients with liver cirrhosis using two 
psychometric tests (Number Connection Test part A, and the Digit Symbol Test) and 
automated analysis of the electroencephalogram (BEG). SHE was defined by the presence of 
at least one abnormal psychometric test andlor abnonnal slowing of the EEG. The influence of 
liver cirrhosis and SHE on patients' daily functioning was assessed using the Sickness Impact 
Profile (SIP) questionnaire. The distribution of SIP scores of the patients with liver cirrhosis 
differed from the reference scores of the general population. Patients with cirrhosis and SHE 
(n~48) reported significantly more impairment in all 12 scales of the SIP, in the psychosocial 
subscore, the physical subscore, as well as in the total SIP score, compared to cirrhotic 
patients without SHE (n~I3I). Multivariate analysis taking into account severity of liver 
disease (Child-Pugh score), presence of varices and alcoholic etiology showed that SHE 
independently was related to a diminished total SIP score. The reproducibility of the SIP was 
high when the test was repeated after a 3-month period. We conclude that SHE implies 
impaired daily functioning and warrants attempts at treatment. 
Introduction 
Clinical manifestations of hepatic encephalopathy include a decreased intellectual 
function, personality disorders, an altered level of consciousness and neuromuscular dysfunc-
tion I In addition to clinical manifest hepatic encephalopathy ,a subclinical stage has been 
described, which cannot be detected through global clinical examination, but requires specific 
neuropsychological and neurophysiological examination. 3·12 The prevalence of subclinical 
hepatic encephalopathy (SHE) is estimated to vary from 30% to 84% according to recent 
studies using appropriate methods. 12·16 This variation in reported prevalence depends on the 
kind (psychometric or electrophysiological) and number of tests used, and the population 
(etiology and severity of the liver disease) tested. 17 
SHE is considered to be clinically relevant for two reasons. First, it could be a preceding stage 
of clinical manifest hepatic encephalopathy. 3 However, this assumption is not proven, because 
only one follow-up study 16 supports this concept. Second, the psychomotor deficits found in 
SHE could have a disadvanting influence on patients' daily functioning, for example in driving 
a car or at work. I ' In view of the reported high prevalence of SHE and its presumed negative 
effect on daily life, routine screening of cirrhotic patients for SHE, and treatment of SHE is 
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recommended. 19·21 However, the need of treatment of SHE is questionable, as a recent study 
has shown that patients with SHE did not perform worse driving 'on the road"than patients 
without SHE. 22 Driving a car is an important, but small part of the total spectrum of daily 
activities. Therefore, on the basis of this study, no conclusions can be made about the effect of 
SHE on other aspects of daily functioning. 
The influence of chronic diseases on daily life can be assessed using 'Health-related Quality of 
life' questionnaires. 23 The 'Sickness Impact Profile' (SIP) questiOlUlalre , is such an 
instrument for overall health assessment and has been used before to deterutine the influence 
of chronic liver disease on patients' daily functioning. 26-29 
The aim of the present study was to determine the prevalence of neuropsychological and 
neurophysiological defects in stable cirrhotic patients attending an university hospital outpa-
tient clinic using two neuropsychological tests and the neurophysiological method of auto-
mated analysis of the electroencephalogram (EEG). The SIP questionnaire was used to 
determine the influence of SHE on daily functioning. In addition, the reproducibility of the SIP 
in cirrhotic patients was determined. 
Patients and methods 
Subjects and Investigations 
From January I, 1992 to May I, 1996202 consecutive patients attending the out-
patient clinic of Hepatogastroenterology of the University Hospital Rotterdam were screened 
for SHE. Inclusion criteria were: histologically proven cirrhosis of the liver and age between 
16 and 80 years. 193 of 202 patients fitted the inclusion criteria; 3 patients had a surgically 
constructed portacaval shunt (no cirrhosis) and 6 patients only had clinical signs of cirrhosis at 
screening. Exclusion criteria were: clinical manifest hepatic encephalopathy *, history of recent 
(less than 6 weeks) alcohol abuse, use of benzodiazepines, anti-epileptics, or other psycho-
tropic drugs, inability to perform the psychometric tests and to complete the SIP questionnaire 
(due to either insufficient knowledge of the Dutch language or bad vision), and severe medical 
problems such as congestive heart failure, pulmonary disease, neurologic desease etc. that 
influence the quality of life measurement. 
1tNote: Clinically manifest hepatic encephalopathy was assmned to be present if at least 2 of the 
following abnornlalities: inverted sleep pattern, impaired calculation, disturbed secundal)' memory, and 
slO\\11ess of speech were detected, or one abnormality in association with a flapping tremor.30 Impaired 
calculation was assessed by asking the patient to subtract serial sevens from 100 and to repeat a series of 
six nonconsecutive numbers in the same order (a nonnal individual can easHy remember seven munbers 
forwards). Memory was tested by asking the patient to remember three objects and to repeat these several 
minutes later, and by asking the patient about past prime ministers, dates of wars, and events that affect 
evcl)'one. 
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In the final analysis, a total of 179 patients with histologically proven cirrhosis of the liver 
were included. 14 patients were excluded because of incomplete SHE screening and/or 
inability to fill out the quality of life questionnaire. All patients underwent a clinical and 
laboratory investigation, psychometric tests, and automated EEG analysis. In addition, the SIP 
questionnaire was administered. All examinations took place on the same day. Test-retest 
reliability of the SIP was assessed by re-administering the questionnaire to patients without 
signs of decompensated liver disease (Le. jaundice, ascites, encephalopathy, or variceal 
bleeding) after a 3-month period. 
Clinical and Laboratory Assessment. 
The Child-Pugh score was used to assess the severity of liver disease. 31 Three bio-
chemical variables (serum albumin, bilirubin and prothrombin time) in addition to the two 
clinical characteristics (presence or absence of ascites and clinical signs of encephalopathy) 
determine the Child-Pugh score. Each variable is given one to three points, leading to scores 
ranging from 5 (excellent liver function) to 15 points (poor liver function). Presence of 
esophageal or gastric varices was evaluated, using reports of endoscopic investigations in 174 
patients, and esophageal X-rays in 5 patients. Alcoholic etiology of liver cirrhosis was defined, 
as: presence of severe alcohol abuse in patient history, and absence of other etiologic factors. 
Neuropsychological Assessment 
Number Connection Test part A (NCT-A). This test is a derivative from the Trail 
Making Test 32 and measures cognitive motor abilities, In the NCT - A patients have to connect 
numbers printed on paper consecutively from 1 to 25. Age-related normal values of this NCT-
A have been developed in 681 persons without liver disease." Normal values are expressed as 
the mean ± 2 standard deviations. After explanation, abbreviated demonstration tests were 
administered to be sure the patient had understood it. Errors were not enumerated, but 
patients were instructed to return to the preceding correct number and then carry on. The test 
score is the time the patient needs to perform the test, including the time needed to correct the 
errors. A low score indicates a good performance. 
Digit Symbol Tesl (DST). This is a subtest of the Wechsler Adult Intelligence Scale 
(WAIS) and measures motor speed and accuracy." The patient is given a list of digits from 1 
to 9 associated with symbols and is asked to fill in blanks with symbols that correspond to 
each number. The test score is the total number of correct sequential matchings of symbols to 
numbers in a 90M second interval. The nonnative data used are expressed as percentiles. After 
explanation of each test, an abbreviated demonstration was administered to ensure that the 
patient understood the test correctly. Data of 2169 Dutch and Belgian healthy controls serve 
as a reference group in The Netherlands" A test result below the 2.5th percentile (Le. the 
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mean minus 2 standard deviations) is considered as abnormal. 
Neurophysiological Assessment 
The EEG was recorded using standardized techniques while the patient, with the eyes 
closed, laid comfortably in a quiet room, When drowsiness occurred an auditory stimulus was 
applied by the EEG technician. Five electrodes were attached to the skin at the positions T3, 
T4, 0 I, 02 and Cz according to the international" 10-20 system" 36. Electrode impedance was 
kept lower than 5kQ. After applying the usual bandpass filters (0.53 - 35 Hz) 2 runs of 100 
seconds each were recorded and compared for reproducibility. Artefact free recordings were 
selected and fed into a computer after AD conversion (sample frequency 102.4 Hz). Ten 
epochs of 10 seconds each were analyzed by applying Fast Fourier Transformation and the 
mean power spectrum calculated. Patients are graded in the different stages of hepatic 
encephalopathy on account of their mean dominant frequency (MDF), and the relative powers 
of delta and theta activity. In a previous study we have validated this method in 51 healthy 
controls (median age 41 years, range 21 - 78) and 66 patients with cirrhosis of the liver 
(median age 60 years, range 21 - 75)." A theta activity above 35% (i.e. the mean plus 2 
standard deviations in controls) is considered abnormal. 
Assessment oj daily fimclioning. 
The SIP questionnaire is an often used instrument that assesses the influence of disease 
and treatment on daily functioning." The questionnaire consists of 136 items, which are 
grouped into twelve scales: sleep and rest, eating, work, home management, recreation and 
pastimes, ambulation, mobility, body care and movement (scores of the latter three may be 
combined as a physical subscore), social interaction, alertness behaviour, emotional behaviour, 
communication (scores of the latter four may be combined as a psychosocial subscore). Apart 
from a 12-dimensional profile score and the physical and psychosocial scores, the SIP provides 
the opportunity to compute a total score. Each score ranges from 0 (best score) to 100 (worst 
score). Patients mark only items that relate to their health at that time. The SIP has been 
translated and validated for the Dutch population.'" 39 
Statistical al/alysis 
Fisher exact test was used to assess differences in sex (male: female), age-group «60 
years: >60 years), Child-Pugh score (A:B/C), etiology of liver cirrhosis (alcohol: other) and 
presence of varices between patients with and without SHE. Difference in median age was 
tested, using Wilcoxon rank sum test. 
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Those variables reaching (borderline) statistical significance in the univariate analysis were 
selected for multivariate analysis, using multiple regression to detennine their influence on 
total SIP score. In this analysis total SIP-scores were logarithmically transformed to reduce 
skewness of distributions. The limit for statistical significance was set at p~0.05. Test-retest 
reliability (reproducibility) was assessed using intra-class correlation coefficients. Values 
above 0.7 generally are considered to indicate good reliability. 40 Internal consistency reliability 
of the SIP scales was assessed using Cronbach's alpha. 41 The internal consistency of a multi-
item scale is a measure of the homogeneity of the items. An alfa of 0.70 is considered to 
demonstrate good internal consistency. " 
Results 
One hundred and seventy-nine patients with histologically proven cirrhosis (113 male, 
66 female, mean age 50 years, SD 14, range 18-77) entered the final analysis. The etiology of 
cirrhosis was chronic viral hepatitis in 71 patients, alcohol abuse in 38 patients, and other 
causes (e.g. auto-immune, PBC, cryptogenic) in 70 patients. None of the patients had 
evidence of neurological and/or psychiatric abnonnalities on global clinical examination 
performed in each patient by one of the first two authors (MG and JCQ). Table 1 summarizes 
the prevalence of abnormality in age-related psychometric tests and automated EEG analysis 
found in the study population. 
Table 1: Prevalence of abnormal neuropsychological, neurophysiological tests and the 
diagnosis of SHE in 179 cirrhotic patients without clinical signs of hepatic 
encephalopathy. 
Nwnber COlUleclion Test A 
Digit Symbol Test 
Automated EEG analysis 
Subclinical Hepatic Encephalopathy 
Number abnormal (%) 
15 (9) 
6 (3) 
34 (19) 
Number diagnosed (%) 
48 (27) 
Forty-eight patients had slowing of the EEG (at least grade I by spectral analysis) and/or at 
least one abnormal psychometric test. These 48 patients were considered as having SHE, 
while the remaining 131 patients were considered not to have SHE. " Clinical and laboratory 
characteristics of both patient groups are summarized in table 2. The male/female ratio did not 
differ between groups. Patients with SHE had a more severe liver disease, as quantified by the 
Child-Pugh score, and more often had esophageal or gastric varices. 
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Moreover, patients with SHE more often had alcoholic etiology of cirrhosis and they tended 
to be older: 55 (36-74) years versus 50 (IS-77)(median age (range» years for cirrhotic 
patients without SHE. However, no difference was found in the number of patients older than 
sixty years of age (table 2). 
Table 2: Clinical and laboratory characteristics of cirrhotic patients with and without 
SHE. 
SHE + SHE- p-value 
(0 = 48) (0 = 131) 
Male/female ratio 36:12 77:54 0.35 
Age (<60:>60) 33:15 97:34 0.57 
Child·Pugh score (A:B/C ratio). 25:23 111:20 <1).001 
Presence of varices: (yes:no)+ 45:3 56:75 <1).001 
Etiology of cirrhosis (alcohol:other)+ 17:31 21:110 0.007 
·sclccted for multivariate analysis (table 4) 
Figure 1 shows the mean SIP scores of patients with and without SHE, compared to reference 
scores of the general population." Patients with cirrhosis and SHE reported significantly 
more impairment in all 12 scales of the SIP, in the psychosocirl subscore, the physical 
subscore, as well as in the total SIP score, compared to cirrhotic patients without SHE (table 
3). Separate analysis of the total SIP score in patients with abnormal psychometric tests, or 
with an abnormal EEG or with both abnormal psychometric tesl(s) and abnormal EEG showed 
equally impaired total SIP scores: for psychometric lests 14 (0.4 - IS.6) for EEG: 11.2 (S.4 -
14), and for both psychometric tests and EEG 13.5 (6.9-20.2) versus 4.6 (3.7 - 5.5) (mean 
(95% CI of mean) for cirrhotic palienls with normal test results (no SHE). 
The results of the SIP scores were similar between the various etiologies of chronic liver 
disease. Although patients with SHE more often had cirrhosis of alcoholic etiology, patients 
with alcoholic cirrhosis did not report more impainnents on the psychosocial, physical or on 
the total SIP score, compared to patients with non-alcoholic cirrhosis (data not shown). 
Possible confounders in the analysis comparing patients with and without SHE could be the 
severity of liver disease (Child-Pugh score, presence of varices) and the etiology of cirrhosis 
(including fatigue as often observed in viral disease and PBC). Therefore, these variables were 
selected for multivariate analysis to evaluate their impact on total SIP score. This analysis 
showed that only presence of SHE and neither the Child-Pugh score, presence of varices nor 
the etiology of cirrhosis significantly affects total SIP score (table 4). 
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Reliability testing of the SIP questionnaire in our patient population using internal consistency 
measures showed that 10 subscales of the SIP fell below the recommended a-coefficient of 
0.70 (table 3). This finding suggests, that the items of these SIP scales are not homogeneous in 
the population of patients with liver cirrhosis; i.e. the items of such a scale do not reliably 
represent an underlying characteristic. "The high internal consistency of the total SIP score is 
at least partly attributable to the high number ofitems. 
The reproducibility of the SIP questionnaire was high as we found a good correlation between 
the SIP results in a 3-month interval (table 5). Minor, statistically not significant, differences of 
mean SIP scores were found between the first and second completed SIP questionnaire, 
indicating that during the 3 months patients had not systematically changed with regard to the 
SIP questionnaire. 
Table 3, SIP scores of cirrhotic patients with and without SHE. 
SIP scales ref, cirrhosis ",ilh SHE cirrhosis without 
(no. of items) group (n=48) SHE (n=13I) l! \'alue Ie 
Psychosocial scales 
Social Interactions (20) 4 14.7 (11.1 - 18.2) 7 (5.3 . 8.6) <1).00 I 0.7 
Alertness (10) 4,7 21.3 (14.3 - 28.2) 8.1 (5.4· 10.7) <1).001 0.8 
Emotional Behaviour (9) 3.9 10.9 (6.5 - 15.4) 5.0 (3.3 -6.7) 0,01 0.6 
Conunwlication (9) 1.0 5.9 (2.8 - 9) 1.5 (0.4 -2.5) 0.001 0.5 
Psychosocial sflbscore 13.3 (9.7· 16.9) 5.7 (4.3-7.t) <1).001 0.8 
Physical scales 
Ambulation (12) 3.0 7 (4.6·9.3) 3.1 (2.1-4.0) 0.002 0.5 
Mobility (10) 2.3 9.4 (5.6·13.1) 2.2 (1.2-3.2) <1).001 0.6 
Bodycare I Movement (23) 1.9 5 (2.9·7.2) 1.2 (0.7-1.6) <1).001 0.6 
Physical slibscore 6.3 (4.1 ·8.5) 1.8 (1.2 - 2.4) <1).001 0.8 
Independent llcales 
SleeplRest (7) 4.7 18.4 (13.5 . 23.4) 8.4 (6.6 - 10.2) <1).001 0.3 
Work (9) 7.3 24.7 (18.3·31.2) 8.7 (5.9 . 11.5) <1).001 0.5 
Home management (10) 4.8 14.6 (9.1·20) 5.9 (4.5·7.3) 0.001 0.5 
Recreations I Pastimes (8) 5.8 23.9 (17·30.8) 9.8 (7.5 - 12.1) <1).001 0.6 
Eating (9) 1.0 5.1 (3.3-7) 2 (1.4 - 2.6) 0.007 0.2 
Total SIP score 3.4 12 (9.5· 14.5) 4.6 (3.7 . 5.5) <1).001 0.9 
Soores are minimally 0 (good perfoffilance) and maximally 100 (bad perfonnance). Mean scores are given; 95% CI 
of mean scores between brackets. Ref. group: reference group 594 dutch citizens (ref. 39). IC: internal consistency 
(Crohnbach u (pooled data». *p-value: Wilcoxon rank sum test. 
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Table 4: Effect of presence of SHE, Child-Pugh score, etiology (alcohol vs. 
non-alcohol) and presence of varices on total SIP score 
variable regression coefficient 9S % confidence Inten'a~ p-value 
SHE 3.7 2.0 - 6.7 <0.001 
child-pugh 1.2 0.66 - 2.2 0.56 
varices 1.4 0.82 - 2.5 0.20 
etiology 0.89 0.49 - 1.7 0.74 
Table 5: SIP scores of38 cirrhotic patients at baseline and after 3months 
T=O monlhs T= 3 months p-value'" Intra-clau 
correlation 
Psycho,wcJallicales 
Social interactions 10 (6.3 - 13.7) 9.6 (6.2 - 13) 0.82 0.84 
Alertness 14 (7.6 - 20.7) 12.6 (5.5 - 19.7) 0.46 0.89 
Emotional Behaviour 8.6 (3.4 - 13.8) 6.9 (3.0 - 10.7) 0.77 0.81 
Conununicalion 4.6 (1.1 - 8.2) 5.1 (0.9 - 9.2) 0.87 0.82 
Psychosocial silbscore 9.6 (5.9 - 13.2) 8.8 (5.1 - 12.6) 0.56 0.94 
Physical scales 
Ambulation 5.8 (3.1 - 8.4) 5.1 (2.5 - 7.8) 0.69 0.88 
Mobility 5.0 (1.5 - 8.5) 5.2 (2.1 - 8.3) 0.85 0.58 
Bodycare I movement 2.9 (1.2 - 4.7) 2.9 (1.1 - 4.6) 0.99 0.88 
Physical slIbscore 4.0 (2.1 - 5.9) 3.7 (2.1 - 5.4) 1.0 0.89 
Independent scales 
Sleep / rest 11.4 (6.3 - 16.5) 9.3 (5.2 - 13.4) 0.56 0.83 
Work 22.9 (15.7 - 30.1) 21.1 (14 - 28.2) 0.67 0.89 
Home management 9.2 (5.6 - 12.7) 11.8 (7.2 - 16.5) 0.53 0.67 
Recreation I Pastimes 14.7 (8.2 - 21.1) 12 (7.1 - 16.9) 0.88 0.67 
Ealing 3.6 (2 - 5.2) 2.6 (1.1-4.1) 0.25 0.58 
Total SIP !lcore 8.5 (5.8 - 11.1) 7.9 (5.3 - 10.5) 0.68 0.96 
Mean scores are given; 95% confidence interval of mean between brackets. Statistics: ·Wilcoxon rank sum test. 
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Discussion 
We performed a study to determine the influence of SHE on the quality of life. Two 
psychomelric tesls with age-related nonnal values (Number connection test part A and Digit 
Symbol Test) and automated EEG analysis were selected to be used as neuropsychological 
and neurophysiological screening tesls for SHE." We defined SHE as presence of at least one 
abnormili psychometric test andlor abnormal slowing of the EEG (at least grade 1 by spectral 
analysis). Using this definition, we found a SHE prevalence of27 % in our outpatient cirrhotic 
population, which is in agreement with the prevalence found in studies using the same 
methods. I)-IS, 17 
We used the SIP as a mel hod for evaluating the influence of SHE on daily functioning in 
cirrhotic patients. as this questionnaire contains items which resemble the complaints seen in 
early stages of hepatic encephalopathy. In add ilion, this questionnaire has been used in a 
previous study in patienls with SHE. 10 
In our study we found a diminished level of functioning in patients wilh SHE, as reflected by 
significantly more impairments in all 12 categories of the SIP. Highest scores were found on 
the categories social interactions, alertness, emotional behaviour, mobility, sleep/rest, home 
management and recreation and pastimes. These are all items which are expected to be 
affected in cognitive disorders. Although the severity and etiology of liver disease could have 
influenced the total SIP scores, multivariate analysis showed that only the presence of SHE 
independently accounls for the total SIP score result. 
Patients with hepatic encephalopalhy grade I can complain about e.g. sleep disturbances, 
impaired calculalion, shortened attention, mild personality changes and muscular 
incoordination. 44 Patients with SHE (in literature considered as a preclinical stage of hepatic 
encephalopathy) should therefore, although to a lesser exlent, have similar complaints in daily 
life. Our findings support this assumplion. 
How reliable are our findings? Firsl, our study was performed in a large sample size (n~ 179), 
which makes the results of the SIP more adequate for slatistical analysis. Second, SHE was 
diagnosed using a combination of neuropsychological and neurophysiological tesls. We only 
used validaled psychomelric lesls wilh age-related normal values, thereby abolishing Ihe 
diagnostic bias caused by aging on neuropsychological performance. ".17 The facl that patienls 
with abnormal psychomelric tests as well as palienls wilh an abnormal EEG showed more 
impairments in daily life, supports the use of both neuropsychological and neurophysiological 
methods for Ihe diagnosis of SHE. Third, we used a validated test to evaluate daily 
functioning, wilh reference values for the Dutch population. In addition, we found a good test-
retest reliability of the SIP in our patient population wilh liver cirrhosis. 
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Figure 1 
II I 
-.with SHE 
...y.. without SHE 
-~reference population 
SHE and daily rUlle/iollillg 
SIP scales 
Mean SIP score in 131 cirrhotic potients without SHE and 48 patients with SHE. compared with 
Ii reference population of594 healthy Dutch volunteers (Jacobs ct ai, ref. 39). 
Fourth, we tried to exclude confounding variables by applying multivariate analysis. Age, 
etiology and severity of liver cirrhosis did not explain the difference in quality of life in 
cirrhotics with and without SHE; this finding also excludes that symptoms as fatigue (a 
common symptom in viral disease and in PBe) explain the observed difference. 
Lastly, our findings are logical. Should we treat patients with SHE because of the diminished 
level of daily functioning found in this study? Up to now, no intervention studies have been 
performed, in which functional status is used as an outcome of treatment efficacy in SHE. 
Treatment of SHE could be beneficial in patients with stable liver disease and impaired 
performance at work or daily life. We therefore strongly suggest the use of 'health-related 
quality of life questionnaires' in trials with treatment specifically directed to SHE. 
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Abstract 
Subclinical hepatic encephalopathy adversely affects daily functioning. To detennine 
which elements of daily life have predictive value for subclinical hepatic encephalopathy, a study 
was perfonned in 179 outpatients with liver cirrhosis. Subclinical hepatic encephalopathy was 
diagnosed using psychometric tests with normal values corrected for age (Number Connection 
Test A and the Digit Symbol Test) and automated analysis of the electroencephalogram (EEG). 
Daily fimctioning was measured with the Sickness Impact Profile (SIP), a quality of life 
questionnaire, containing 136 statements. Patients with and without SHE were compared for 
differences in response to all statements by univariate analysis, and subsequently by multivariate 
analysis of potential discriminating statements. SHE was diagnosed in 48 patients (27%). Thirty-
six statements were significantly more often true for patients with subclinical hepatic 
encephalopathy. Multivariate analysis showed, that five statements of the SIP related to alertness, 
sleep and rest, flne motor skills and work, have independent predictive power for subclinical 
hepatic encephalopathy. Combining these statements predictive for subclinical hepatic 
encephalopathy with patient characteristics enables physicians to assess the probability of 
subclinical hepatic encephalopathy in the individual cirrhotic patient. 
Introduction 
The clinical syndrome of hepatic encephalopathy (HE) is characterized by disturbance of 
mental state and neuromuscular function. In clinical practice, hepatic encephalopathy is classified 
in four grades; with progressively more advanced deterioration of mental state with each grade. 1 
In addition to clinically manifest HE, a subclinical stage has been described. 2·' The prevalence 
of subclinical hepatic encephalopathy (SHE) is estimated to vary from 14% in patients with Child-
Pugh A cirrhosis to 45% in patients with Child-Pugh B/C cirrhosis, according to recent studies 
using appropriate methods 3· '. The clinical relevance of SHE is still subject to debate. Evidence 
is increasing that SHE adversely affects daily functioning. ~1 
In the recent study, the effect of SHE on daily functioning was tested, using the Sickness Impact 
Profile (SIP). 1 The SIP is a generic, non disease-specific quality of life questionnaire. • 
We hypothesized that the SIP questionnaire contains a number of statements on daily functioning, 
that could be specifically abnormal in SHE. Identification of a subgroup of cirrhotic patients with 
a high probability of SHE by simple means would be clinically relevant, since confirmatory testing 
by neuropsychological and neurophysiological methods can then be limited considerably. In the 
present study we analysed the value of selected SIP statements for the diagnosis of SHE. 
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Patients and methods 
Patients 
Bedside diagnosis of SHE 
From January 1, 1992 to May 1, 1996 202 consecutive patients attending the outpatient 
clinic ofHepatogastroenterology ofthe University Hospital Rotterdam were screened for SHE. 
Inclusion criteria were: histologically proven cirrhosis of the liver and age between 16 and 80 
years. 193 of 202 patients fitted the inclusion criteria; 3 patients had a surgically constructed 
portacaval shunt (no cirrhosis) and 6 patients had only clinical signs of cirrhosis at screening. 
Exclusion criteria were: clinical manifest hepatic encephalopathy *, history of recent (less than 6 
weeks) alcohol abuse, use of benzodiazepines, anti-epileptics, or other psychotropic drugs, 
inability to perform the psychometric tests and complete the SIP questionnaire (due to insufficient 
knowledge ofthe Dutch language or bad vision), and severe medical problems such as congestive 
heart failure, pulmonary disease, neurologic disease etc. that influence the quality of life 
measurement. In the final analysis, a total of 179 patients with histologically proven cirrhosis of 
the liver were included. 14 patients were excluded because of incomplete SHE screening and/or 
inability to fill out the SIP questionnaire. 
All patients underwent a clinical and laboratory investigation, psychometric tests, and automated 
EEG analysis. In addition, the SIP questionnaire was administered. 
Methods 
Diagnosis of SHE. SHE was defined as the presence of at least one abnormal psychometric test 
and lor abnormal slowing of the electroencephalogram (EEG) .• 
Number Connection lest part A (NCI-A) Ihe NCI-A is a derivative from the lrail Making lest 
11 and measures cognitive motor abilities. Patients pert'orm the test by connecting numbers printed 
on paper consecutively from 1 to 25. Age-related normal values of the NCI-A have been 
developed in 681 persons without liver disease. 12 A test is considered abnormal, if the time 
needed to perform the test is above the 97.5th percentile of the age-group. 
"'Note: Clinically manifest hepatic encephalopathy was assmnoo to be present if at least 2 of the follO\""ing 
abnormalities: inverted sleep pattem, impaired calculation, disturbed secondary memory, and slowness of 
speech were detected, or one abnOmHtlity in association with a flapping tremor.9 Impaired calculation was 
assessed by asking the patient to subtract serial sevens from 100 and to repeat a series of six nonconsecutive 
numbers in the same order (a normal individual can easily remember seven numbers forwards). Memory was 
tested by asking the patient to remember three objects and to repeat these several minutes later, and by asking 
the patient about past prime ministers, dates of wars, and events that affect evel)'one. 
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Digit Symbol Test (PSD TillS is a subtest ofthe Wechsler Adult Intelligence Scale (WAIS) and 
measures motor speed and accuracy. "The patient is given a list of digits associated with symbols 
from 1 to 9 and is asked to fill in blanks with symbols that correspond to each number. Age-
related normal values have been developed in 2169 Dutch and Belgian control subjects without 
liver disease. 14 A total number of symbols below the 2.5th percentile of the age-group is 
considered as abnormal. 
Spectral analysis of the EEG. The EEG was recorded using standardized techniques. Five 
electrodes were attached to the skin at the positions T3, T4, 01, 02 and Cz according to the 
international "10-20 system". Electrode impedance was kept lower than 5kQ. After applying the 
usual bandpass filters (0.53 - 35 Hz) 2 runs of 100 seconds each were recorded and compared for 
reproducibility. Artefact free recordings were selected and fed into a computer afier AD 
conversion (sample frequency 102.4 Hz). Ten epochs of 10 seconds each were analysed by 
applying Fast Fourier Transfomlation and the mean power spectrum was calculated. Patients are 
graded in the different stages of hepatic encephalopathy on account of their mean dominant 
frequency (MDF), and the relative powers of delta and theta activity. " A theta activity above 
35% (Le. the mean plus 2 standard deviations in controls) is considered abnormal. 
Assessment of daily functjoning. The Sickness Impact Profile (SIP) was used to assess daily 
functioning. The questiOIUlaire consists of 136 statements, which are grouped into twelve scales: 
sleep and rest, eating, work, home management, recreation and pastimes, ambulation, mobility, 
body care and movement, social interaction, alertness behaviour, emotional behaviour and 
communication. 12 Each score ranges from 0 (best score) to 100 (worst score). Patients are 
instructed to mark only items that relate to their health at that time. It takes a patient about 20 
minutes to complete the SIP. The SIP questionnaire has been validated for the Dutch population 
16,17 
Liyer function assessment. The Child-Pugh score was used to assess the severity of liver disease. 
10 Three biochenllcal variables (serum albumin, bilirubin and prothrombin time) in addition to two 
clinical characteristics (presence or absence ofascites and clhllcal signs ofhepatic encephalopathy) 
determine the Child-Pugh score. Each variable is given one to three points, leading to scores 
ranging from 5 (excellent liver function) to 15 points (poor liver function). Presence of esophageal 
or gastric varices was evaluated using reports of endoscopic investigations in 174 patients, and 
esophageal X-rays in 5 patients. Alcoholic etiology of liver cirrhosis was defined as: presence of 
severe alcohol abuse in patient history, defined as at least 6 drinks a day for several years. 
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Statjstical analysis. Fisher exact test was used to assess differences in sex (male:fernale), age-
group (age under 60 years versus older than 60 years), Child-Pugh group (A:B/C), etiology of 
liver cirrhosis (alcohol: other) and presence of esophageal varices between patients with and 
without SHE. The differences of each of the 136 statements of the SIP separately was tested, 
using the Fisher exact test. Statements which differed between groups in univariate comparisons 
(p<0.05) entered into multivariate analysis (backward elimination logistic regression, using the 
package LOGXACT), together with the patient characteristics: age-group, sex, Child-Pugh score, 
etiology and presence of esophageal varices. Regression coefficients of those variables with 
predictive power for SHE (p<0.05) were used to construct a SHE score. 
The true positive rate (sensitivity) and the false positive rate (J - specificity) of the total 
SIP score, the score of the statistically significant statements, and of the SHE score were 
evaluated, by calculating the receiver operating characteristic (ROC). A ROC curve shows the 
relationship between the true positive rate and false positive rate ofa diagnostic test. Every point 
on the curve represents the characteristics ofa certain Hcut-offpoint" of the test. A test without 
discriminatory capacity for two groups would give a line of 45 degrees. The greater the 
discriminatory capacity of the test, the more the curve will approach the point which represents 
1000/0 true positive rate and 0% false positive rate. A test without discriminatory capacity has an 
area under the curve (AUC) of 0.50; a perfect test would have an AUC of 1.0. In clinical practice 
diagnostic tests usually have an AUC ranging from 0.60 to 0.90. " 
Results 
One hundred and seventy-nine patients with histologically proven cirrhosis (113 male, 66 
female, mean age 50 years, SD 14, range 18-77) entered the study. The etiology of cirrhosis was 
chronic viral hepatitis in 71 patients, past alcohol abuse in 38 patients, and other causes (e.g. auto-
immune, PBC, cryptogenic) in 70 patients. Forty-eight out of 179 patients were diagnosed as 
having SHE (27%). Twenty-one patients (12%) either had one or two abnormal psychometric 
tests and 34 patients (19%) had abnormal slowing of the EEG. Ten patients (6%) had an 
abnormal psychometric test as well as abnormal slowing ofthe EEG. 
No difference in sex ratio, nor in age group (age under 60 years of age versus 60 years 
and older) between cirrhotic patients with and without SHE was found (data not shown). 
Cirrhotic patients with SHE had a more severe liver disease (percentage of patients with Child-
Pugh B/C: 48 % vs. 15 % (p<O.OOI); percentage of patients with esophageal varices: 94 % vs. 
43 % (p<O.OOI); in addition, more patients with SHE had an alcoholic etiology of liver disease 
(35 % vs. 16 % (p~0.OO7)). Univariate analysis of each of the SIP statements showed, that thirty-
six out of 136 SIP statements were significantly more frequent in patients with SHE (table I). 
105 
2,3 
Table 1 
Category 
ambulatian 
mobility 
bodycarcl 
movement 
Bedside diagnosis of SHE 
SIP statements significantly different for SHE positive and negative patients selccted for 
multivariate analysis 
SHE+ SHE -
Statement (n=l8) (n=131) 
I. I walk more slowly. 46 24 
2, I walk shorter distances or stop to rest often. 21 4 
3, I walk by myself but with some difticuity, for 
example, limp, wobble, stumble, have stiff leg. 11 I 
4, I am staying in bed more. 11 2 
5, I am staying in bed most of the time. 6 0 
6, I stay away from home only for brief periods oftimc. 11 5 
7, I do not fasten my clothing, for example. require 
assistance with buttons, zippers, shoelaces. 6 0 
8. I stand only for short periods oftime. 11 7 
9, I change position frequently. 19 8 
10, J do not have control of my bowels. 8 I 
II. I have trouble getting shoes, socks or stockings on. 11 I 
social interactions 12, My sex'Uai activity is decreased. 58 27 
Il, I am going out less to visit people. 42 22 
14, I am cutting dO\\llthe length of visits with friends. 29 14 
15, I often express concern ovcr what might be 
happening to my health. 27 11 
16, I stay alone much of the time. 25 9 
17, I show less interest in othcr people's problems, for 
example, don't Iistcn when they tell me about their 
problems, don't offer to help. 17 4 
alertness 18, I am confused and start sc\'cral actions at a time.. 23 1 
19, I react slowly to things that are said or done. 25 5 
20, I sometimes behave as if I were confused or 
disorientatcd in place or time, for example, whcre I 
am, who is aroWld, directions, what day it is. 11 2 
21, I forget a lot, for example, things that happened 
reccntly, where I put things, appointments. 46 15 
22, I do not keep my attention on any activity for long. 21 11 
emotional 21, I act irritable and impatient with myself, for example, 
behaviour talk badly about myself. swear at myself, blame 
mysclf for things that happen. 23 9 
24, I often moan and groan in pain or discomfort. 15 4 
25, I keep rubbing or holding areas of my body that hurt 
or are Wlcomfortable. 27 5 
comntWlication 26, I am having trouble writing or typing. 11 1 
sleep and rest 27, I am slceping or dozing most of the time· day .and 10 0 
night. 
28, I spend much of the day lying down in order to 
rest. 15 0 
29, llie dO\\1l more often during the day in order to rest. 40 19 
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Table 1 (continued) 
home management 30, 
31. 
32, 
recreation/ 33, 
pastime 
34, 
35, 
work 36, 
Bedside diagnosis o[SHE 
I am not doing any of the regular work around the 
house that I would usually do. 10 
I ha\'c difficulty doing handwork, for example, 
turning fauceh, using kitchen gadgets, 9cwlng, 
carpentry. 13 
I am not doing any of the clothes washing that I 
would usually do. 8 
I am cutting donn on some of my usual inactive 
recreation and pastimes, for example. watching TV. 
playing cards, rcading 23 
I am going Qut for entertainment less oilen. 36 
I am not doing any of my usual physical recreation 
or activities. 29 
I am not workJng at all. SO 
2 
2 
7 
17 
9 
IS 
In the multivariate analysis, the predictive power of the 36 selected statements over that 
of the Child-Pugh score, age, sex, etiology of liver disease, and presence of esophageal varices 
was evaluated, Five statements (table I: no, 18, 21, 28, 31 and 36) had independent predictive 
value for SHE. On the basis of this analysis, a formula for a SHE score was constructed. 
Subsequently, the relation between the probability of SHE and the SHE score was analysed; the 
result is graphically presented in figure I, together with four examples, ROC analysis shows, that 
both the total SlP score (AUC = 0,78) as well as the score ofthe 36 statements (AUC = 0,81) are 
able to differentiate patients with and without SHE (figure 2), The ROC curve of the SHE score 
has highest discriminatory capacity for SHE (ROC=0,91), This underlines, that the predictive 
value of the SHE score for the diagnosis SHE is markedly improved by combining information 
from the SlP questionnaire with patient charactenstics that reflect the prevalence of the syndrome, 
A cut-off level of 3,3 for the SHE score leads to a sensitivity of 90%, The false positive 
rate associated with this cut-olflevel equals 24%, If the cut-olflevel is chosen in such a way that 
a sensitivity of99"10 is obtained (SHE score of I ,2), the false positive rate increases considerably 
(up to 85 %), 
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SHE 
Items factor score probability of SHE 
statement:" I am confused and start 1.8 
several actions at a time" probabUlty (%) 
100 
statement: " I forget a lot, e.g. things 1.1 
that happened recently, where I put 
things, appointments " 75 
statement: " I spend much of the day 3.7 
lying down in order to rest " so 
statement: " I have difliculty doing 
handwork, for example, turning faucets, 
1.9 
25 
using kitchen gadgets, sewing. 
carpentry " 0 .-~ 
0 2 4 6 • 10 12 14 
!itatement: "I am not working at all " 1.3 SHE store 
Male!lcx 1.2 
Child-Pugh' 7 (H/C) 1.6 
varices pretlcnt 2.1 
--
TOTAL SCORE: 
-
Examples SHE score p 
No statements, male sex, Child-Pugh A varices present: -. 3.3 14% 
No statements, male sex, Child-Pugh C, varices present: 
-
4.9 46% 
Statement I and 2 present, male sex, Child-Pugh C, varices present: 
-
7.8 95% 
Statements 1-5 present. male sex, Child·Pugh C, varices present: 
-
14.7 100% 
Figure 1: Calculation and interpretation of the SHE score. The SHE score is calculated as follows: male 
cirrhotic patient: 1.2 is added up to score; Child-Pugh B/C: 1.6 is added up to score~ presence of 
esophageal varices: 2.1 is added up to score; presence of either of the 5 statements: factors are added 
up to score. With the calculated SHE score the probability of SHE can be derived from the figure. 
Four examples illustrate the applicability of the SHE score. 
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Figure 2: 
Discussion 
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Diagnostic capacity of the SHE score (D), tile score ofllIe 36 statistical signiHcant SIP statements 
(+) and the total SIP score (0) for the diagnosis SHE (ROC curves). 
Cirrhotic patients with SHE report more impairments on daily functioning using the 
Sickness Impact Profile questionnaire. Evaluation of the 136 separate statements showed that 36 
statements are marked more often by SHE patients. After detailed statistical analysis five 
statements were selected as predictive for SHE. These five questions in combination with patient 
characteristics as sex, Child-Pugh score and presence of esophageal varices will allow physicians 
to estimate the probability of SHE and subsequently order confirmatory tests .. 
Setting the cut-off level of the SHE score at 3.3 (90% sensitivity) implies an acceptable 
percentage of false positives (24 %). At a sensitivity of 99% the false positive rate increases 
considerable (up to 71 %), which is not acceptable for an initial screening test. 18 
In this study SHE was diagnosed by using a combination of neuropsychological and 
neurophysiological tests. Internationally, there is an ongoing debate over how to diagnose SHE. 
We used well validated methods with normal values corrected for age, that yielded a low 
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percentage of SHE positives in Child-Pugh A cirrhotics, and appreciable numbers in Child-Pugh 
B/C cirrhotics. ' We think that this combination oftests is clinically appropriate for the diagnosis 
of SHE, although in the future some adaptations may be needed in view of international 
consensus, 4,5 
Symptoms of early hepatic encephalopathy - a term which might replace the term subclinical 
hepatic encephalopathy - include: memory (impaired computation), affect (euphoria or 
depression), attentiveness, language, judgement and cognitive function, inversion of sleep pattern, 
and muscular incoordination (impaired handwriting). ,., The list of36 statements that were the 
basis for the multivariate analysis indicates, that most impairments are found in the categories: 
alertness (forgetfulness, confusion, attentiveness), sleep and rest (sleeping, dozing during the day), 
home management (handwork) and communication (writing and typing) (table I). The statement: 
" I do not work at all " also had predictive power for SHE; 50% of cirrhotic patients with SHE 
did not have regular employment, compared to 15% of patients without SHE. 
The five statements with predictive value are most usethl when assessed in the light of additional 
risk factors: severity of liver disease (Child-Pugh score) and portal hypertension (esophageal 
varices). This reflects the variation in predictive value of the test in relation to the prevalence of 
the syndrome. The relation between SHE and the severity of liver disease has been described 
previously. 4,19,20 In addition,the presence of portal-systemic shunting is a well-known risk factor, 
even in the absence of cirrhosis. 21 
This study suggests, that the probability of SHE can be estimated simply at the bedside or in the 
outpatient clinic. Only cirrhotic patients with a high probability for SHE should undergo 
electrophysiologic and psychometric tests to confirm the diagnosis. The SHE score can be used 
for the diagnosis of SHE, but might also be of value in intervention studies for SHE. 
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Abstract 
Subclinical hepatic encephalopathy may have prognostic significance with regard to 
the development of clinical hepatic encephalopathy and survival. We studied 116 consecutive 
patients with histologically proven cirrhosis of the liver for subclinical hepatic encephalopathy, 
using Number COImection Test A, Digit Symbol Test and spectral analysis of the 
electroencephalogram. Twenty-five patients (22%) were diagnosed as having subclinical hepatic 
encephalopathy. Patients with subclinical hepatic encephalopathy were older, had a higher Child-
Pugh score, more often had esophageal and/or gastric varices and episode(s) of clinical hepatic 
encephalopathy in history. During a median follow-up of29 months (range 1-49 months) patients 
with subclinical hepatic encephalopathy significantly more often had episodes of clinical hepatic 
encephalopathy. Survival, however, was similar to patients without subclinical hepatic 
encephalopathy, and was mainly determined by the Child-Pugh score. The Child-Pugh score was 
also superior to subclinical hepatic encephalopathy in predicting episodes of clinical hepatic 
encephalopathy. Therefore the prognostic significance of subclinical hepatic encephalopathy 
appears limited. 
Introduction 
The spectrum of hepatic encephalopathy traditionally includes four stages. I,' More 
than twenty years ago, the presence of mental impairment preceding clinical hepatic 
encephalopathy has been suggested.' This preclinical stage, in which patients with cirrhosis 
demonstrate neuropsychological or neurophysiological deficits, without altered mental state or 
neurological abnommJities on global clinical examination, was later defined as subclinical hepatic 
encephalopathy (SHE). H The prevalence of SHE varies between 30 - 84% in patients with liver 
cirrhosis, dependent on the diagnostic criteria used.solO A combination of neuropsychological and 
neurophysiological parameters appears most appropriate for the diagnosis of SHE,'" since both 
methods probably assess different brain functions. 10 The significance of the diagnosis SHE is 
subject to debate. 8,IO,11 Recent studies show, that SHE has a negative influence on daily 
fUllctioning. 11,12 In addition, several investigators suggest, that there is a relation between SHE 
and the subsequent development of episodes of clinical hepatic encephalopathy. 4,7,13 However, 
studies on the natural history of SHE and its prognosis with respect to development of clinical 
hepatic encephalopathy and survival are lacking. 4,10 In the present study we therefore focussed 
on the natural history and prognostic significance of SHE with respect to development of clinical 
hepatic encephalopathy and survival. 
114 
2.4 
Patients and methods 
Paliellis 
Prognosis o(SllE 
From January 1, 1992 to December 31, 1993, 117 consecutive patients with 
histologically proven cirrhosis visiting the outpatient clinic of the department of 
Hepatogastroenterology in our hospital, were screened for SHE. Patients with clinical signs of 
hepatic encephalopathy (impaired intellectual function, altered level of consciousness, personality 
disorders andlor neuromuscular dysfunction (asterixis», as well as patients with signs of 
neurological and/or psychiatric abnonnalities on global clinical examination were excluded. 
Patients with a history of recent excessive alcohol abuse, patients using psychotropic drugs (e.g. 
benzodiazepines, anti-epileptics) were also excluded. The closing date offollow-up was the first 
outpatient visit following January I, 1996. If death occurred before the closing date, the time 
between screening and date of death was considered as the follow-up period. If routine check-up 
at the outpatient department was discontinued, or if the next appointment was made in the second 
half of 1996, the patient's general practitioner was contacted to obtain the missing data. 
The median period of observation was 29 months (range 1 - 49 months). One hundred and 
seventeen patients entered the study. One of the 117 patients was lost offollow-up shortly after 
screening for SHE, and therefore did not enter the study. The patient characteristics at entry of 
the 116 remaining subjects are listed in table l. Liver transplantation (15 patients), shunt-
operations (6 patients) andlor TIPS (7 patients) were regarded as an event, indirectly expressing 
the severity of the liver disease, and therefore patients undergoing these interventions were not 
excluded from the analysis. 
The etiology of liver disease was divided in chronic viral hepatitis, alcohol abuse, and other causes 
(e.g: auto-immune hepatitis, primary biliary cirrhosis). At entry, the severity of liver disease was 
assessed in all patients, using the Child-Pugh score. At entry, in 107 patients presence (85 
patients) or absence (22 patients) of oesophageal varices was documented. Patients were 
considered as having decompensated cirrhosis at entry if one of the following complications were 
present in the patient history: variceal bleeding. jaundice, ascites and clinical hepatic 
encephalopathy. Variceal bleeding was diagnosed, using the following criteria: signs of 
haematemesis andlor melena, gastric aspirate containing blood, and the following findings at 
endoscopy: active bleeding varix or endoscopic signs of recent variceal bleeding, without evidence 
for other sources of gastro-intestinal bleeding. 14 Ascites was defined as present, if there was 
ascites on clinical examination (shifiing dullness), andlor on abdominal ultrasonography. 
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Methods 
Diagnosis of SHE. SHE was defined as presence of at least one abnormal psychometric test and! 
or abnormal slowing of the electroencephalogram (EEG). • 
Number Connection Iest part A (NCI-A) Ihe NCI-A is a denvative from the Irail Making Iest 
16 and measures cognitive motor abilities. Patients perform the test, by connecting numbers 
printed on paper consecutively from I to 25. Age-related normal values of the NCI -A have been 
developed in 681 persons without liver disease. 17 A test is considered abnormal, if the time 
needed to perform the test is above the 97.5th percentile of the age-group. 
Digit Symbol Iest (PSI) Ihis is a subtest of the Wechsler Adult Intelligence Scale (W AIS) and 
measures motor speed and accuracy. 10 Ihe patient is given a ust of digits associated with symbols 
from 1 to 9 and is asked to fill in blanks with symbols that correspond to each number. Age-
related normal values have been developed in 2169 Dutch and Belgian control subjects without 
liver disease. H A total number of symbols below the 2.5th percentile of the age-group is 
considered as abnormal. 
Spectral analysis of the EEG. Ihe EEG was recorded using standardized teclmiques. Five 
electrodes were attached to the skin at the positions T3, I4, 0 I, 02 and Cz according to the 
international "10-20 system". Electrode impedance was kept lower than 5kQ. After applying the 
usual bandpass filters (0.53 - 35 Hz) 2 runs of 100 seconds each were recorded and compared for 
reproducibility. Artefact free recordings were selected and fed into a computer after AD 
conversion (sample frequency 102.4 Hz). Ien epochs of 10 seconds each were analysed by 
applying Fast Fourier Transfonnation and the mean power spectrum was calculated. Patients are 
graded in the different stages of hepatic encephalopathy on account of their mean dominant 
frequency (MDF), and the relative powers of delta and theta activity. " A theta activity above 
35% (i.e. the mean plus 2 standard deviations in controls) is considered abnormal. 
Assessment of Iiyer fimctioD. The Child-Pugh score was determined to assess the severity of 
cirrhosis, including three biochemical variables (serum albumin, bilirubin, and prothrombin time) 
and two clinical characteristics (presence or absence of ascites and clinical hepatic 
encephalopathy). 19 Ihe Child-Pugh score ranges from 5 points (excellent liver function) to 15 
points (poor liver function). A patient has a Child-Pugh A cirrhosis, if the score is < 6 points; 
Child-Pugh B if it is 7 - 9 points and Child-Pugh C if the score is > 9 points. Patients without 
signs of ascites, but on diuretic treatment because of previous ascites scored 2 points for ascites 
in the Child-Pugh score. In the final analysis patients with Child-Pugh Band C were pooled, as 
the number of Child-Pugh C patients was too low to justity separate grouping. 
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Outcome measure, Survival status and clinical hepatic encephalopathy were assessed at the end 
offollow-up. OfaU patients who died during follow-up, the cause of death was documented and 
defined as liver related death if death was the direct consequence of the patient's underlying liver 
disease. All other causes of death were considered as non-liver disease related. Episodes of 
clinical hepatic encephalopathy were classified as precipitated, if the episode occurred in the 
course of e.g. gastro-intestinal bleeding, constipation, infection or psychotropic medication. If 
no other cause than the underlying cirrhosis could be found, the episode of clinical hepatic 
encephalopathy was considered endogenous. 
Statjstjcal analysis. Differences in clinical and laboratory characteristics between groups were 
tested with the Wilcoxon rank sum test or Fisher Exact test. The incidence of clinical hepatic 
encephalopathy as well as other decompensating events in patients was analysed using the Kaplan-
Meier method. In the survival analysis only liver-related deaths were counted. The effect of 
patient characteristics at screening (presence of SHE, Child Pugh score, age, and clinical hepatic 
encephalopathy in history) was tested using logrank tests. Those variables with borderline 
significance (p~O.05) were selected for Cox regression analysis, to estimate the independent 
prognostic significance of each of the selected variables. 
Results 
At screening, 25 of 116 (22%) patients were diagnosed as having SHE. Sixteen 
patients had an abnormal spectral EEG, and nine patients had one or two abnormal psychometric 
test results; 3 patients had both an abnormal spectral EEG and abnomlal psychometric testes). 
Patients with SHE were older and had a more severe liver cirrhosis at entry, as quantified by the 
Child-Pugh score. In addition, esophageal and gastric varices were more ofien seen in patients 
with SHE. Nineteen patients (76%) with SHE had a past history of decompensated cirrhosis at 
entry, compared to 52 patients (57%) without SHE. Patients with SHE more often had episodes 
of clinical hepatic encephalopathy in history. Other signs of decompensation in history Gaundice 
or ascites) were equally distributed in both groups (table 1). 
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Table 1 Patient characteristics at entry (n = 116) 
Total group SHE + SHE- p-
Age (mean±SDCrange» 49 ± 14 (17-77) 59 ± \I (36-77) 46± 14.0 (17--73) 0.006 
Sex (m:/) 85:31 19:6 66:25 0.8 
Etiology (N (%» 
viral 58 (50) \I (44) 47 (52) 0.84 
alcohol 22 (19) 8 (32) 14 (15) 0.17 
other 36(31) 6 (24) 30 (33) 0.64 
Child-Pugh (N (%» 
A 81 (70) \I (44) 70 (77) 
B/C 35 (30) 14 (56) 21 (23) 0.003 
Vance>< (N (%» 85 (79) 23 (92) 62 (67) 0.02 
Interval between histological 51 (0-258) 29 (0-184) 57 (0-258) 0.29 
diagnosis and entry 
(median (range» 
Past history of decompensated 71 (61) 19 (76) 52 (57) 0.1\ 
cirrhosis (N (%» 
encephalopathy \I (9) 7 (28) 4 (4) 0.002 
variceal bleeding 32 (28) 10 (40) 22 (24) 0.13 
jaWldice 40 (34) 6 (24) 34 (37) 0.24 
ascites 43 (37) \3 (52) 30 (33) 0.1 
Ten patients with SHE at screening showed signs of clinical hepatic encephalopathy during 
follow-up, compared to 6 patients without SHE (actuarial percentage at three years: 56% and 8% 
respectively; p<O.OOI), (figure I, table 2). Separate analysis of precipitated episodes and 
endogenous episodes of clinical hepatic encephalopathy showed, that precipitated episodes were 
seen in 4 patients with SHE and in 2 patients without SHE (actuarial percentage at three years: 
13% and 3% respectively; p~O.008). 
Non-precipitated episodes of clinical hepatic encephalopathy were seen in 6 patients with SHE, 
versus 4 patients without SHE (actuarial percentage at three years: 32% and 5% respectively; 
p---o.OO6). Five out of II patients with episodes of clinical hepatic encephalopathy in history had 
clinical hepatic encephalopathy during follow-up, compared with II out of 105 patients without 
clinical hepatic encephalopathy in history (actuarial percentage at three years: 46% versus 21%; 
p~O.OI). 
ll8 
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Table 2 
Follow-up (mean (range» 
Prognosis o/SHE 
Mean follow-up, number of decompensating events after follow-up, 
liver related death and total death. 
SHE + SHE- p-value 
(N=2S) (N=91) 
25.6 (2·39) 28.8 (t·49) 0.21 
Decompensating events in follow-up (%) 
encephalopathy JO (40) 6 (7) <O.OOt 
variceal-bleeding 3 (t2) JO (II) 1.0 
jmmdice 2 (8) 8 (9) 1.0 
ascites 5 (25) 15 (t6) 0.09 
Liver related death 4 (16) 5 (6) 0.43 
Total death 6 (24) 12 (t 3) 0.22 
Fourteen out of35 patients with Child-Pugh score B/C cirrhosis and 2 patients with Child-Pugh 
A cirrhosis developed clinical hepatic encephalopathy during follow-up (actuarial percentage at 
three years: 58% and 4% respectively; p<O.OOI). In Child-Pugh B/C patients a trend was found 
to more clinical hepatic encephalopathy in patients with SHE (actuarial percentage at three years: 
78% versus 38%; p~O.12). For patients with Child-Pugh A cirrhosis, such a trend could not be 
found. Although patients with SHE were older than patients without SHE, no relation between 
the development of clinical hepatic encephalopathy and age could be found (data not shown). 
100 
90 
!;j 80 
] 70 60 0 
'a 50 ~ 40 ~ 
~ 30 
20 
Figure 1 
~I)'r __ -'~"'O"-J) 
10 20 
months 
SHE poslth"e 
SHE negalh"e 
~') 
30 40 
Probability of clinical hepatic encephalopathy 
in patients with SHE (p<O.OOI: logrank test) 
119 
2.4 Prognosis o[SHE 
Evaluating the factors SHE, Child-Pugh score and clinical hepatic encephalopathy in Illstory with 
regression analysis, we found that both SHE and Child-Pugh score are independent predictors for 
the development of clinical hepatic encephalopathy (table 3). 
During the period of observation eighteen patients died. In 9 cases death was due to progressive 
liver failure (n~I), hepatocellular carcinoma (n~3) and acute gastro-intestinal bleeding (n~5). In 
9 patients death was related to extrahepatic causes: malignancies (n~3), fatal bleeding from 
duodenal ulcer (n~I), cardiac decompensation (n~3), and suicide (n~I). No differences in 
death rates during follow-up were seen between SHE positive and SHE negative patients (table 
2). Figure 2 shows the actuarial survival of patients with SHE versus patients without HE; no 
significant difference was found (JFO.26). Actuarial survival of patients with Child-Pugh A versus 
Child-Pugh B/C was however highly significant (p~O.002), indicating that the Child-Pugh score 
is a much better prognostic marker for cirrhosis than SHE. Cox regression analysis was used to 
estimate the independent effect of Child-Pugh score, age, presence of SHE and clinical hepatic 
encephalopathy in history on survival. This analysis showed, that the Child-Pugh score is the 
only prognostic factor with respect to survival (RR for Child-Pugh score: 13 (CI: 2.4 -70.5; 
p=0.OO3), age: 0.9 (CI: 0.15 - 4.9; p=0.86), SHE: 1.2 (CI: 0.24 - 6.3; p=0.80) and clinical 
HE in history: 0.9 (CI: 0.16 - 5.2; p=0.93». 
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Table 3 Relative risk of child-pugh DIC, clinical hepatic encephalopathy in history and 
Ule diagnosis SHE at entry on clinical hepatic encephalopathy during follow-up 
Entry reature Clinical hepatic encephalopathy during follow-up 
Relative Risk 95%CI p-value 
SI-ffi (positive vs. negative) 3.7 1.2 - II 0.02 
Child-Pugh (HIC vs. A) 19.3 4.1 - 90.8 <0.001 
Clinical HE in history (present vs. absent) 0.67 0.2 - 2.2 0.5 
Discussion 
Interest in the syndrome of subclinical hepatic encephalopathy has increased markedly 
in the last decade. Many diagnostic tests have been proposed to diagnose this condition. However, 
the prognostic significance of SHE is largely undefined. In this study we found that patients with 
SHE have a 3.7 times increased risk to develop clinical hepatic encephalopathy. However, the 
Child-Pugh score is superior to SHE in predicting the development of clinical hepatic 
encephalopathy. Survival analysis showed, that the Child Pugh score is the only independent 
predictor for liver related deaths. Thus, in order to estimate overall prognosis of patients with 
cirrhosis, the Child-Pugh score should be used. 2I-23 
How reliable are our findings? 
We studied the prognostic significance of SHE in a large sample of patients with cirrhosis (n~ 116) 
and with a follow-up of29 months. Methods for diagnosing SHE vary; therefore the outcome 
may be related to the way the patient population was divided. However, the prevalence of SHE 
in this cohort of patients was 22% and SHE was more often diagnosed in older patients with more 
advanced liver cirrhosis, which is comparable \vith other studies.6,s,II,I) Also, the outcome variable 
clinical hepatic encephalopathy is defined in various ways_ No differences were found between 
the groups with endogenous and precipitated episodes of clinical hepatic encephalopathy with 
respect to SHE and clinical hepatic encephalopathy in history; therefore, all episodes of clinical 
hepatic encephalopathy were pooled. On the basis of our resuits, we can conclude that patients 
with SHE are prone to develop clinical hepatic encephalopathy. SHE appears to be a latent form 
of chronic encephalopathy; in this stage exacerbations of liver disease or extrahepatic 
complications lead to episodes of clinical hepatic encephalopathy. 
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What do our findings imply for the cirrhotic patient with SHE? 
Overall, a cirrhotic patient with SHE has an increased risk to develop clinical hepatic 
encephalopathy. The risk is highest in older cirrhotics with Child-Pugh B/C and with esophageal 
varices. Preventive treatment for clinical hepatic encephalopathy in patients with SHE should be 
evaluated, especially if daily functioning is affected. II The principal factor for increasing survival 
in cirrhosis is to prevent progression of liver disease by eliminating the etiological factor Of by 
liver transplantation. 
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Discussioll and COllc/us;om 
In 1994, when the investigations summarized in this thesis started, unresolved issues in 
hep~tic encephalopathy were: til'c"pathophysiology and subclinical hepatic encephalopathy. At 
the end of 1998 the pathophysiology remains largely unresolved; however, the issue of subclinical 
hepatic encephalopathy has been clarified for the major part. 
Pathophysiological .spects 
In tillS thesis several aspects ofthe pathophysiology ofI-IE were subject to investigation: 
ammonia-induced alterations in glutamate neurotransntission, structural brain damage, the GABA-
benzodiazepine receptor complex and thyroid hormone metabolism. 
An intervention study with the NMDA-receptor antagonist MK-801 indicated, that glutamate 
toxicity has no causative relation with the pathophysiology, since blocking of post-synaptic 
NMDA receptors does not reduce symptoms ofI-IE, nor does it affect survival. Despite these 
results, glutamate neurotransmission remains a topic for future research: Firstly, because 
experiments with another glutamate antagonist (memantine) showed improvement in symptoms 
ofI-IE in rats with acute liver failure and anunonia infusion; I probably, memantine is much better 
tolerated than MK-801. Secondly, our observation, that blocking the post-synaptic NMDA 
receptor induces symptoms of HE in control animals, and enhances the development of 
encephalopathy in animals with acute liver failure and acute hyperammonemia suggests, that 
decreased, rather than increased glutamate neurotransmission could have a role in the 
pathophysiology. Modulation of post-synaptic NMDA-receptors by excess extracellular glutamate 
could be an explanation for this observation.' 
Iffi is still believed to be a reversible neuropsychiatric syndrome. 3 However, studies on 
autopsied brain tissue of cirrhotic patients who died in hepatic coma has shown selective loss of 
glial fibrilla!)' acidic protein (GFAP) in grey matter and Alzheimer type II gliosis. '.' In addition, 
this selective decrease in GF AP can be induced in cultured astrocytes, by exposing them to 
ammonia 6 • In the study on neuronal and glial marker protein low molecular NF68 breakdown 
products in the hippocampus of rabbits with h~'~el Jmmonemia and with acute liver failure were 
observed, suggesting some structural changes in the brain were actually present. Hypothetically, 
the experimental models used may have had a too limited survival time for extensive structural 
brain damage to become detectable. Structural brain damage in HE remains a topic, especially 
since both neurophysiological and neuropsychological deficits remain present in some patients 
after liver transplantation (unpublished observations). 
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From the very first moment it came to light, the GABA-benzodiazepine hypothesis has 
been generally well received. However, controlled trials with benzodiazepine antagonists showed 
no major effect on hepatic encephalopathy, except if encephalopathy is precipitated by exogenous 
benzodiazepine use. Endogenous benzodiazepines play no major role in the pathophysiology of 
hepatic encephalopathy, and flumazenil is ol~y indicated in patients with cirrhosis and 
encephalopathy precipitated by benzodiazepine use. 
Does our finding mean that the GABA-benzodiazepine hypothesis can be discarded? 
The answer is no. Studies with the partial inverse agonist sarmazenil in a dog model of chronic 
HE showed improvement in clinical signs of HE and in mean dominant frequency of the EEG; 
flumazenil was not effective in the same dog model.' These results cannot be explained by 
endogenous benzodiazepine-like substances, nor by exogenous benzodiazepine use. Probably, 
sarmazenil modulates the GABA-receptor directly, ' or it interferes with peripheral-type 
benzodiazepine repectors. 9 Peripheral-type benzodiazepine receptors are located on the outer 
membrane of mitochondria of astrocytes and microglia. Binding to these receptors leads to 
enhanced production of neurosteroids (e.g. pregnenolone, tetrahydroprogesterone) by facilitating 
the transport of cholesterol. In experimental models of HE these receptors are up-regulated. This 
enhanced neurosteroid synthesis is of interest, because these substances have a extremely potent 
positive modulatory effect on GABA receptors. In addition, these neurosteroids inhibit the uptake 
of GAB A and glutamate into astrocytes. 10 Future research on GABA neurotransmission within 
the area of the pathophysiology of HE should especially be directed to the peripheral 
benzodiazepine antagonists and their effect on neurosteroid synthesis. 
A case control study, performed at our department, showed that triiodothyronine (T,) has 
strong predictive power for HE" In addition, a case control study suggested, that 
supplementation ofthyroid hormone may improve portal-systemic encephalopathy. l2 The study 
on thyroid hormone metabolism included in this thesis does not solve the issue of altered thyroid 
hormone metabolism and its implications for the pathophysiology of HE. In non-thyroidal illness, 
the uptake ofT, in the brain may be affected by the same inhibitory substances that compromise 
uptake into hepatocytes."·" The concept of "local brain hypothyroidism" as factor in the 
pathophysiology of hepatic encephalopathy should be a topic for future research, especially 
because thyroid hormones affect postsynaptic glutamate - and both central and peripheral 
benzodiazepine receptor function. IS· 17 
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Of the three other potential fields in the pathophysiology of HE mentioned in the 
introduction, glutamine accumulation is the most consistent finding, Glutamine is synthesized in 
astrocytes out of ammonia and glutamate by the enzyme glutamine synthetase. This is the only 
pathway in the brain for ammonia detoxification, II • 20 Glutamine accumulation results in 
astrocytic swelling and brain edema formation. This concept is supported by the finding, that 
blocking glutamine synthetase with methionine sulfoximine prevents brain swelling in rats after 
portacaval anastomosis. 21·22 However, methionine sulfoximine induces seizures in these animals, 
probably because glutamate is not converted to glutamine and accumulates extracellularly. 21 As 
a concept for future studies in experimental hyperammonemia and acute liver failure, both 
blocking glutamine synthesis and at the same time blocking post-synaptic NMDA receptors could 
learn us more about the role of both glutamine and glutamate in the pathophysiology of HE. 
Figure I summarizes the three major mechanisms potentially involved in the 
pathophysiology of HE, that could be focus offuture investigations. 
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Subclinical hepatic encephalopathy 
The area of SHE can be divided in diagnosis, implications, and therapy. With regard to 
the diagnosis, the problem was how to recognize SHE. Applying time-consuming 
neuropsychological and neurophysiological test batteries to each cirrhotic patient at the outpatient 
department is not feasible. In addition, in the standard tests advocated previously, 23·26 normal 
values were not corrected for age, which resulted in a considerable number offalse positives. 27 
At our department, a combination of psychometric tests (Number Connection test A and Symbol 
Digit Test; both with age-corrected normal values) and one neurophysiological test (automated 
EEG analysis) was used. SHE was defined present, if at least one psychometric test was abnormal 
andlor ifthere was abnormal slowing of the EEG. Applying these criteria to an unselected group 
of \37 patients with cirrhosis showed a prevalence of SHE of23 %. In addition, the prevalence 
of SHE increased significantly from 14 % of patients with Child-Pugh A cirrhosis, to 45 % of 
patients with Child-Pugh B or C cirrhosis. " 
Separate analysis of the Sickness Impact Profile yielded five statements, which can be used for 
screening the outpatient population for SHE. After initial screening, a subgoup of patients with 
a high probability of SHE can thus be selected for more specific testing: either with psychometric 
tests or neurophysiological tests. The types of specific tests should in our opinion be at least one 
psychometric test and one neurophysiological test, provided that normal values corrected for age 
are available. Under these conditions, the precise type of specific test used will be dependent on 
local practice. 
The first study addressing the clinical implications of SHE postulated, that the psychomotor 
defects found in patients with SHE had a negative effect on the fitness to drive. 29 In tillS study, 
40 cirrhotic patients underwent extensive neuropsychological testing (24 tests, 102 variables 
studied I). On the basis these tests, the authors concluded, that 60 % of the cirrhotics were unfit 
to drive a car and that the driving capacity of 25 % was questionable. 29 Unfortunately, the 
investigators do not describe the method used to assess driving fitness. This initial concept on 
driving capacity and SHE was however not confirmed by recent studies. 3O.3I In the latter study, 
the driving capacity of9 cirrhotic patients with SHE was tested, using a driving simulator and a 
real driver's examination Hon the road)). Results indicated, that patients with SHE did not drive 
less well when compared with 15 healthy control subjects. " 
We decided to apply a quality of life questionnaire to evaluate the clinical implications of SHE. 
Results indicate, that daily function is significantly impaired in patients with SHE. In addition, 
separate analysis of the statements of the Sickness Impact Profile questionnaire yielded five 
statements on daily life specifically directed to SHE. These five statements, together with clinical 
variables, are now used to select cirrhotic patients with a high probability of SHE (see above). 
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Another clinical implication of the diagnosis SHE refers to its natural history. It has been 
suggested in literature, 25.32 that SHE may be a prelude to clinically overt HE. However, long-
term follow-up studies of cirrhotic patients with SHE were not available. The results of our 
prognostic study indicate, that patients with SHE have an increased risk to develop clinical HE, 
but that prognosis is determined by the Child-Pugh score. 
Lastly, one major issue on SHE remains unresolved: Can SHE be treated? Several intervention 
studies using nonabsorbable saccharides, 33 ·36 dietary manipulation, 25,37 and branched~chain 
amino acids (BCAA)'~39 have been performed, all of which document some improvement in SHE. 
Reliable interPretation ofthese studies is hampered by differences in the populations studied, the 
diagnostic criteria used and by learning effects in the psychometric tests. 27 At our own 
department, a placebo-controlled trial with low-dose lactulose for six months in cirrhotic patients 
without HE and hyperammonemia (arterial ammonia above 30 flmol/L) showed no effect on 
arterial ammonia levels, psychometric tests, nor on the EEG. Interestingly, a significant 
improvement in the psychosocial subscore of the SIP was found in both experimental groups. The 
investigators suggest, that a higher dose of lactulose could be effective in cirrhotic patients with 
a confirmed diagnosis of SHE and an impaired quality of life. 40 
To fully estimate the efficacy oftreatment strategies for SHE, symptoms of SHE should be the 
principal outcome measure, and psychometric tests or neurophysiological tests should be 
secondary outcome measures. 
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CONCLUSIONS 
I. Glutamate toxicity has no major role in the pathophysiology of hepatic encephalopathy, 
2. Encephalopathy as a result of acute liver failure and acute hyperammonemia is not 
associated with structural changes in the brain, 
3. Treatment with the benzodiazepine antagonist flumazenil indicates, that endogenous 
benzodiazepines have no major role in the pathophysiology of hepatic encephalopathy; 
flumazelul is indicated only if encephalopathy is precipitated by benzodiazepines use, 
4. Low triiodothyronine and thyroxine level&in dogs with portal-systemic encephalopathy 
indirectly suggest, that brain uptake of these substances is also affected. 
5. Automated electroencephalogram analysis to diagnose (subclinical) hepatic 
encephalopathy can be performed at random hours during the day, 
6. Subclinical hepatic encephalopathy has a significant adverse effect on daily functioning, 
7. Cirrhotic patients can be screened for subclinical hepatic encephalopathy, using a symptom 
checklist of five statements in combination with clinical variables. The diagnosis should 
be confirmed by psychometric tests and automated EEG analysis, 
8. Patients with subclinical hepatic encephalopathy have an increased risk to develop 
clinically manifest hepatic encephalopathy. The Child-Pugh score is superior to subclinical 
hepatic encephalopathy with respect to prognosis. 
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In tillS thesis several aspects of the pathophysiology of HE were subject to investigation: 
ammonia-induced alterations in glutamate neurotransmission, structural brain damage, the 
GABA-benzodiazepine receptor complex and thyroid hormone metabolism; 
In citapter 1.1 results are presented of measurement of neuronal (NF-68, NF-200, 
NSE) and glial marker proteins (GFAP, S-IOO) in the brain of rabbits with acute liver failure 
and acute hyperammonemia. Increased proteolysis of these marker proteins reflects structural 
brain damage. The content of neuronal and glial cell markers was not affected by either of the 
two experimental conditions. However, low molecular weight proteolytic fragments of the NF 
68 kD polypeptide were observed in the hippocampus of three out of six animals in both 
experimental conditions, indicating minor neurofilament degeneration. These findings indicate, 
that no extensive structural brain damage occurs in the cours of acute liver failure and acute 
hyperammonemia. 
In chapter 1.2 the implication of increased extracellular brain glutamate levels on the 
pathophysiology of HE was tested. In a placebo-controlled experiment, the efficacy of the 
glutamate antagonist MK-80 1 was evaluated in rabbits with acute liver failure and acute 
hyperammonemia. A dose of MK-801 of 0.05 mlJkglhr enhanced the development of HE in 
both experimental groups, and induced encephalopathy in the control rabbits. Survival was not 
affected by MK-801 treatment. The results do not give support to the hypothesis, that 
increased extracellular glutamate has a causative role in the pathophysiology of HE. 
In citapter 1.3 alterations in thyroid hormone metabolism in HE was 
evaluated. In dogs with a portacaval shunt and partial hepatectomy serum levels of 
triiodothyronine (T3) thryoxine (T4), free T4, rT3, T4-sulphate and T3-sulphate were 
measured it baseline and at four weeks after surgery. pes dogs developed clinical signs of HE, 
hyperammonemia and hypalbuminemia after four weeks. T4 and T3 levels decreased 
significantly, and T4-sulphate degradation was significantly diminished. 
Free T4 , reverse-T3 and T3-sulphate levels remained unaltered. HE is accompanied by low T4 
and T3 levels and normal free T4 levels. Low serum levels of T3 could be the result of 
decreased hepatic synthesis (diminished DI activity), decreased hepatic uptake of T4 or by 
diminshed plasma binding of both T3 and T4. It is suggested, that specific inhibitors of plasma 
binding of thyroid hormone - like bilirubin and L-amino acids - also compromise hepatic 
uptake ofT4. In addion, the same inhibitory substances could affect brain uptake ofT4, which 
could have role in the pathophysiology of HE. 
In citapter 1.4 the efficacy of the benzodiazepine antagonist flumazenil was assessed 
clinically and electrophysiologically in a double blind, randomized, placebo-controlled 
multicentre study in patients with HE. Patients who were positive for benzodiazepines were 
excluded. This study primarily focussed on the effect on the EEG, next to clinical improvement 
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of HE. EEG gradings of five out of 17 (29%) flumazenil treated patients showed an 
improvement in EEG-grading compared to two out of 15 (13%) placebo treated patients. In 
conclusion, endogenous benzodiazepine have no major role in the pathophysiology of HE. 
Flumazenil is indicated only, if encephalopathy is precipitated by exogenous benzodiazepines. 
The four studies on subclinical hepatic encephalopathy (SHE) included in this thesis 
focussed on the diagnosis and the implications of the syndrome; 
In chapter 2.1 a study is presented, in which the variability in the EEG 
and the effect of meals and physical exercise was evaluated in patients with cirrhosis without 
HE, with SHE and with HE. Therefore, 12 hour portable EEG registration and repetitive 
automated analysis of the EEG (spectral analysis) was performed. EEG recordings were also 
graded by visual inspection. No significant differences in mean dominant frequency (MDF) and 
percentage theta activity were observed during the morning, after lunch, after exercise, or after 
dinner. On the basis of visual inspection slowing of the EEG was observed after lunch in the 
majority of patients with SHE and in half of patients with clinically manifest HE. Assessment of 
patients with cirrhosis by EEG is hardly influenced by time of the day, meals or exercise, when 
assessed by MDF and percentage theta activity. EEG grading by visual inspection is a more 
sensitive method to detect variability in the EEG. However, changes in consciousness during 
the day reported by patients with cirrhosis rather reflect physiological variability than 
aggravation of HE. Therefore, automated EEG analysis can be performed at random hours 
during the day. 
In chapter 2.2 the influence of SHE on patients' daily functioning was assessed using 
the Sickness Impact Profile (SIP). Patients with SHE reported significantly more impairments 
in all 12 scales of the SIP, in the psychosocial subscore, the physical subscore, as well as in the 
total SIP score, compared to cirrhotic patients without SHE. Multivariate analysis taking into 
account severity of liver disease (Child-Pugh score), presence of varices and alcoholic etiology 
showed that SHE independently was related to a diminished total SIP score. 
In chapter 2.3 an effort was made to determine which statements of the SIP have 
predictive power for SHE. Therefore, patients with and without SHE were compared for 
differences in response to all statements of the SIP. This analysis yielded thirty-six statements 
that were significantly more often true for patients with SHE. After multivariate analysis, five 
statements of the SIP (related to alertness, sleep and rest, fine motor skills and work) showed 
to have independent predictive power for SHE, together with the patient characteristics: Child-
Pugh score, oesophageal varices and male sex. An SHE score was constructed, containing the 
five statements and the patient characteristics. With this score the probability for SHE can be 
assessed, making it a bedside screening test for SHE. 
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In chapter 2.4 the prognostic significance of SHE with regard to the development of 
HE and survival was evaluated. Patients with SHE were older, had a higher Child-Pugh score, 
more often had esophageal and/or gastric varices and episode(s) of clinical HE in history. 
During a median follow-up of 29 months (range 1-49 months) patients with SHE significantly 
more often had episodes of clinical HE; survival however, was similar to patients without SHE, 
and was mainly detennined by the Child-Pugh score. The Child-Pugh score was also superior 
to SHE in predicting episodes of clinical HE. The prognostic significance of SHE appears 
limited. 
In the Discussion and Conclusions chapter the significance of the studies on the 
pathophysiology are discussed, and three major mechanisms potentially involved in the 
pathophysiology are presented: glutamine accumulation in the brain and its role in cerebral 
edema formation, astrocyte dysfunction, altered glutamate neurotransmission and the role of 
increased neurosteroid synthesis in GABA neurotransmission. Future research should focus on 
these three mechanisms. The issue of subclinical hepatic encephalopathy (SHE) has been 
resolved for the major part. The diagnosis, implications and therapeutic options for SHE are 
discussed. With the proposed SHE score an initial screening test for SHE is presented, with 
which SHE can be diagnosed on the basis of symptoms related to daily functioning. 
Therapeutic options of SHE should be evaluated in the future. in which symptoms of SHE 
should be the primary endpoint. 
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In dit proefschrift zijn verschillende aspecten van de pathotysiologie van hepatische 
encephalopathie (HE) belicht: ammoniak-gemedieerde veranderingen in glutamaat 
neurotransmissie. structurele hersenbeschadiging, de col van het GABA-benzodiazepine 
receptor complex en het schildklierhonnoon metabolisme; 
In hoofdsluk 1.1 zijn de resultaten gepresenteerd van metingen van specifieke neuronale 
(NF-68, NF-200, NSE) en gliale (GFAP en S-IOO) eiwitten in de hersenen van konijnen met 
acute leverinsufficientie en acute hyperammoniemie. Verhoogde atbraak van deze eiwitten zijn 
een teken van hersenbeschadiging. De lotale inhoud van de neuronale en gliale eiwitten bleef 
onveranderd in beide experimentele modellen. In de hippocampus van drie van de zes konijnen 
in beide groepen werden echter laag-moleculaire eiwitfragmenten van het NF-68 gevonden. 
Deze bevining duidt op beginnende hersenbeschadiging. De resultaten geven aan, at er geen 
sprake is van uitgebreide hersenbeschadiging in het beloop van acute leverinsufficientie en 
acute hyperanunoniemie. 
In hoofdsluk 1.2 werd in een placebo-gecontroleerd experiment het effect van de 
glutamaat antagonist MK-801 geevalueerd op tekenen van encephalopathie en overleving van 
konijnen met acute leverinsufficientie en acute hyperammoniemie. Een dosering van MK-801 
van 0.05 mg/kg/uur versnelde het ontwikkelen van encephalopathie in beide experimentele 
modellen, en induceerde encephalopathie in controle konijnen. De overleving werd niet 
be'invloed door MK-801. De resultaten geven aan, dat verhoogde extracellulaire levels van 
glutamaat geen oorzakelijke relatie heeft met de pathotysiologie van HE. 
In hoofdsluk 1.3 werden veranderingen in het schildklierhormoon metabolisme 
onderzocht. In honden met een portacavale shunt en een partiele leverresectie werden aan het 
begin van het experiment en vier weken na de operatie de serumwaarden van triiodothyronine 
(T3), thyroxine (T 4), vrij T4, reverse-TJ, T4-sulfaat en TJ-sulfaat bepaald. De IlOnden hadden 
vier weken na de operatie allen teken van encephalopathie. hyperammoniemie en 
hypalbuminemie. T4 en T3 waren significant verlaagd en de a!braak van T4-sulfaat was 
significant afgenomen. Vrij T4, rTJ en TJ-sulfaat bleven gelijk. De resultaten geven aan, dat 
HE gepaard met een laag T4 en TJ. Laag TJ kan een gevolg zijn van verminderde synthese in 
de lever (vemlinderde DI activiteit), verminderde opname van T4 in de lever of door 
verminderde eiwitbinding van TJ en T4. De suggestie is, dat specifieke renuners van de plasma 
binding van schildklierhormoon - zoals bilirubine en L-aminozuren - ook de opname van T4 in 
de lever remmen. Bovendien kunnen dezelfde remmers verantwoordelijk worden geacht voor 
een verminderde opname van T4 in de hersenen, hetgeen van betekenis kan zijn voor de 
pathotysiologie van HE. 
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In hoofdstuk 1.4 is de effectiviteit van de benzodiazepine antagonist flumazenil 
onderzocht in een dubbel-blind, placebo-gecontroleerd multieentrische studie in patienten met 
HE. In deze studie werd met name gekeken naar verbetering van het electroencephalogram 
(EEG), naast klinische verbetering van HE. Bij aile patienten was het gebruik van 
benzodiazepines uitgesloten. Het EEG verbeterde bij vijf van de zeventien (29%) patienten, 
vergeleken met twee van de vijftien patienten, behandeld met placebo. Klinische verbetering 
werd waargenomen bij drie van de vijf behandelde patienten met een EEG verbetering. De 
conclusie is, dat endogene benzodiazepines geen grote rol spelen in de patho/ysiologie van HE, 
en dat behandeling met flumazenil aileen ge'indiceerd is, als er sprake is van benzodiazepine 
gebruik. 
De vier studies over subklinische hepatische encephalopathie (SHE) die onderdeel vormen 
van dit proefschrift, richten zich op de diagnose en de betekenis van het syndrome; 
In hoofdstuk 2.1 wordt een studie gepresenteerd, waarin de variabiliteit van het EEG en 
de invloed van maaltijden en Iiehaamsbeweging onderzocht is bij patienten met levercirrose 
zonder HE, met SHE en met HE. Hiertoe werd gedurende 12 uur een ambulante EEG 
registratie gemaakt en werd met intervallen spectraal analyse verricht van het EEG, Tevens 
werd het EEG visueel beoordeeld, Er werden geen signifleante veranderingen in de mean 
dominant frequency (MDF), noch in het percentage theta gevonden gedurende de oehtenduren, 
na de lunch, na Iiehaamsbeweging, en na het avondeten. Op basis van visuele beoordeling van 
het EEG werd echter EEG vert raging vastgesteld na de lunch in bijna aile patienten met SHE 
en in de helft van de patienten met HE. De conclusie is, dat de evaluatie van (S)HE met behulp 
van spectraal analyse van het EEG (MDF en percentage theta) nauwelijks bei"nvloed wordt 
door het moment van de dag, maaltijden, noeh door de mate van Iichaamsbeweging. Evaluatie 
van het EEG door visuele beoordeling is een gevoeliger methode om variabiliteit in het EEG te 
deteeteren, De veranderingen in bewustzijn, die worden gerapporteerd door patienten met 
cirrose gedurende de dag lijken echter eerder een /Ysiologische variabiliteit te zijn, dan 
variabiliteit in ernst van encephalopathie. Spectraal analyse van het EEG bij patienten met 
levercirrose en (S)HE kan dan ook op elk willekeurig moment van de dag worden uitgevoerd. 
In hoofdstuk 2.2 werd het effect van SHE op het dagelijks fimctioneren onderzocht met 
de Sickness Impact Profile (SIP). Patienten levercirrose en SHE rapporteerden significant meer 
afwijkingen op aile twaalf schalen van de SIP, op de psychosociale subscore, de /Ysieke 
subseore, alsook op de totale SIP score, in vergelijking met cirrose patienten zonder SHE, 
Multivariaat analyse met de totale SIP score, de ernst van leverziekte (Child-Pugh score), de 
aanwezigheid van varices en alcohol als etiologie toonde aan, dat de diagnose SHE 
onafhankelijk gerelateerd is aan een verhoogde totale SIP score. 
141 
Summary. Samenvatting 
In hoofdsluk 2.3 werd uilgezochl welke beweringen van de SIP vragenJijsl voorspeUende 
waarde hebben voor de diagnose SHE. Hiertoe werd bij patienten met en zonder SHE 
verschillen in response op aUe SIP beweringen afzonderlijk geevalueerd. 36 van de 136 
beweringen van de SIP bleken significant vaker door patienten met SHE te worden 
aangekruist. Na muitivariaat analyse bleken vijf beweringen (verband houdend met alertheid, 
slap en en rusten. fijne motoriek, en werk) en de patient karakteristieken: Child-Pugh score, 
aanwezigheid van slokdarmvarices en het manJijk geslacht voorspeUende betekenis te hebben 
voor de diagnose SHE. Op basis van deze analyse werd een SHE score gemaakt, waarmee de 
kans op SHE kan worden ingeschat. Hiennee kan op eenvoudige wijze voor aanwezigheid van 
SHE worden gescreend. 
In hoofdsluk 2.4 is de prognostische betekenis van SHE met betrekking tot het 
ontwikkelen van HE en overleving geevalueerd. Patienten met SHE waren ouder. hadden een 
hogere Child-Pugh score, hadden vaker varices en hadden tevens vaker episoden van HE 
doorgemaakt in de voorgeschiedenis. Na een gemiddelde follow-up van 29 maanden (range 1 -
49 maanden) maakten patienten met SHE vaker episoden door van HE. De overleving was niet 
verschillend tussen patienten met en zonder SHE en werd bepaald door de Child-Pugh score. 
De Child-Pugh score was ook superieur boven SHE in het voorspellen van episoden van HE. 
De conclusie is, dat patienten met SHE een verhoogd risico hebben op het ontwikkelen van 
HE, maar dat de prognose bepaald wordt door de Child-Pugh score. 
In de Discussie en Conclusies wordt de betekenis van de studies inzake de 
pathofysiologie van HE besproken. Tevens worden een aantal mechanismen gepresenteerd, die 
mogelijk een belangrijke rol spelen in de pathorysiologie: glutamine ophoping in de hersenen en 
de rol hiervan bij de vorming van cerebraal oedeem, astrocyten dysfunctie. veranderingen in 
glutamaat neurotransmissie en de rol van verhoogde synthese van neurosteroiden op GABA 
neurotransmissie. 
Tevens worden de diagnose, de betekenis en de behandelingsopties van SHE besproken. 
Met de voorgestelde SHE score kan SHE worden gediagnostiseerd aan de hand van 
symptomen, die gerelateerd zijn aan het dagelijks functioneren. Behandelingsopties voor SHE 
dienen nader te worden geevalueerd. waarbij deze symptomen als primair eindpunt dienen te 
worden gebruikt. 
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